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Abstract 
 
The fundamental coordination chemistry of rhenium still has a pivotal role to play 
towards the development of functional rhenium radiopharmaceuticals with target-
specific biodistribution patterns. One of the numerous design considerations to take 
into account is the use multidentate chelators that can potentially stabilize 
oxorhenium(V) complexes but also offer a manner of which to manipulate the 
hydrophobicity and lipophilicity of rhenium complexes through derivatization of 
their multidentate chelators. In contrast to these oxorhenium(V) complexes which 
are prone to oxidation to [ReO4]- by water, rhenium(I) complexes containing the 
facial tricarbonyl rhenium(I) core, fac-[ReI(CO)3]+ are typically stable in aqueous 
media. Furthermore, the chemical inertness and the small size of the fac-[ReI(CO)3]+ 
core relative to the size of Re(V) core  makes it ideal for the design of novel rhenium 
radiopharmaceuticals. In addition, the remaining coordination sites of the fac-
[ReI(CO)3]+ core could be utilized for coordination to scaffolds incorporating 
biological entities which can potentially manipulate the biodistribution patterns of 
formulated rhenium(I) radiopharmaceuticals. The integrated and bifunctional design 
approaches towards rhenium radiopharmaceutical design will need to be enforced 
which involves the inclusion of biologically relevant moieties in multidentate 
chelators or attachment of biological relevant moieties to bifunctional chelators.  
 
In chapter 3, the coordination behaviours of multidentate diimines encompassing 
chromone moieties are considered. The formation of a novel rhenium (I) complex, 
fac-[Re(CO)3(chrpychr)] (1) from the equimolar coordination reaction between [2-(4-
oxo-4H-chromen-3-yl)-5H-chromeno[2,3-d]pyrimidin-5-one] (chrpychr) and 
[Re(CO)5Br]. In addition, the formation and characterization of a novel dinuclear 
rhenium(I) compound, fac-(Re(CO)3Br)2(μ-chret) (2) [chret = N, N‘-bis((2-amino-3-
imino)methylenechromone-1,2-ethane] and a mononuclear  metal complex,  fac-
[Re(CO)3(bzch)Br] (3) [bzch = 2-benzimidazole-4H-chromen-4-one]. The metal 
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complexes were characterized by 1H NMR-, IR-, UV-Vis, melting point and 
conductivity measurements. The solid-state structures for the metal complexes were 
confirmed via single crystal X-ray analysis. The simulated IR spectra for the 
respective metal complexes provided insight in the interpretation of their 
corresponding experimental spectra. 
 
Chapter 4 entails the isolation of  novel rhenium(I) and -(V) complexes with 
perimidine ligands incorporating fused N-donor heterocyclics. The equimolar 
coordination reactions of 2-(benzothiazole)-2,3-dihydro-1H-perimidine (bzpm) and 
2,3-dihydro-2-(pyridine)-1H-perimidine (pypm) with [Re(CO)5Br] afforded the 
rhenium(I) complexes: fac-[Re(CO)3(bzpm)Br](1) and fac-[Re(CO)3(pypm)Br](2), 
respectively. The oxo-free rhenium(V) complex, cis-[Re(pyrnp)Br2(PPh3)](3) 
{H3pyrnp = 8-((1H-pyrrole)iminomethyl)naphthalene-1-amine} was isolated from the 
reaction of trans-[ReOBr3(PPh3)3]with two-fold molar excess of 2,3-dihydro-2-(1H-
pyrrole)-1H-perimidine (pyrpm). These metal complexes were characterized via 1H 
NMR-, IR-, UV-Vis spectroscopy, melting point and conductivity measurements. 
Single crystal X-ray analysis provides a definitive confirmation of the structural 
elucidations of the metal complexes. The DNA binding interactions of the rhenium(I) 
metal complexes were evaluated through UV-Vis titrations with Calf-Thymus (CT)-
DNA. 
Keywords: Rhenium, Spectral Characterization, Crystal Structure, DFT studies, 
Perimidine, pyrrole, chromone, benzothiazole DNA binding. 
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Chapter 1 
Introduction 
1.1 General background: 
The continued expansion on the coordination chemistry of rhenium reflects its 
diverse applications in radiopharmacy, catalysis and bioluminescence [1-3]. The 
main attribute owing to rhenium’s various applications, it’s the fact that metal 
complexes with oxidation states ranging from −1 to +7 have been reported, e.g. 
NH4ReVIIO4 [4-5]. This chemical versatility is emphasized in a number of robust 
chemical cores which can stabilize rhenium in high (e.g. [ReN]3+, [ReO]3+ and 
[ReO4]+) and low (e.g. fac-[Re(CO)3]+ and [ReCl3]3+) oxidation states [4].  Furthermore, 
the in vivo and in vitro bio-imaging capabilities of the low spin d6 rhenium(I) 
complexes arises from its optimal photochemical properties [6]. Among the 
numerous catalytic rhenium compounds, methyltrioxorhenium (MTO) have been 
widely studied in the epoxidation of olefins and as catalytic oxidants [7].  
 
In addition, the β-emitting 186/188-rhenium radionuclides have well-suited half-
lives and β-max energies for the treatment of malignant growths in the body [8]. 
However, there are still challenges to design rhenium radiopharmaceuticals that can 
be synthesized via one-pot methods in high yields. In addition, other design criteria 
like charge, size, lipophilicity and hydrophobicity that influence the biodistribution 
of potential rhenium radiopharmaceuticals should also be taken into account [9]. 
Moreover, current design strategies for manipulating the biodistribution of a 
metallopharmaceuticals, is to incorporate a biologically active moiety in the 
coordination sphere of the metal complex or to make use of a bifunctional chelator 
which coordinates to the metal centre and covalently link to the biologically active 
moiety [9, 10].  
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1.2 Aim and motivation: 
The imperative of designing organorhenium compounds with biologically relevant 
moieties arises from the requirement that the next generation of rhenium 
radiopharmaceuticals must have target-specific biodistribution patterns [9].  Thus, 
we have investigated the design, syntheses, characterization and DNA binding 
studies of facial tricarbonylrhenium(I) and rhenium(V) complexes with multidentate 
chelates incorporating various biologically relevant moieties. These biologically 
relevant moieties includes chromone, benzothiazole, pyrrole and 1,3-
dihydroperimidine, see Figure 1.1. 
NH S
N
O
O
HN NH
pyr bz chr
pm  
Figure 1.1: Structures of the biologically active moieties (BAMs): pyrrole (pyr), 
benzothiazole (bz), chromone (chr) and 1,3-dihydroperimidine (pm). 
 
The chromone moiety is an important pharmacophore for a large number of 
pharmaceuticals with a variety of medicinal applications [11]. Typical examples 
include 3,7-substituted chromones (see, Figure 1.2) which have shown to be effective 
obesity suppressants and these molecules functions through binding to the melanin-
concentrating hormone receptor 1 (MCH1R) [12]. Furthermore, the chromone moiety 
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is naturally occurring constituent found in the plant kingdom as secondary 
metabolites which allow chromone-derived drugs to be physiological biocompatible 
in cells while rendering diverse pharmacological activities in the treatment of several 
diseases. The aforementioned is illustrated by an alkaloid, Rohitukine extracted from 
the leaves and stems of Amoora Rohituka. This alkaloid exhibits antiinflammatory 
and immunomodulatory properties while showing moderate cytotoxicity against 
human HL-60 (viz. promyelocytic leukemia) and HCT-116 (viz. colon cancer cells) 
[11]. Furthermore, the isolation of rhenium(I) and –(V) compounds with chromone 
mono-imines have been successful and this provides an  impetus for exploring the 
coordination behaviour of chromone diimines towards the [ReVO]3+ and fac-
[ReI(CO)3]+ cores [13, 14]. 
 
Pyrroles can be found in various marine natural products, e.g. the Caribbean sponge 
Agelas cerebrum containing various bromopyrrole alkaloids (see Figure 1.3) which 
have showed optimal anticancer against various human tumour cells and 
antimalarial activities against various malaria strains [15-19].  
Synthetic molecules containing the benzothiazole group have shown to exhibit 
unique structure-activity relationships. For example, the bis-benzothiazole 
derivatives showed superior herbicidal activities than their structural analogues 
containing one benzothiazole moiety each [20]. In a survey of a series of 
benzothiazoles, it was been discovered that the benzothiazole derivative, 11C-
labelled 2-(4-methylaminophenyl)-6-hydroxybenzothiazole (known as Pittsburgh 
Compound B, see Figure 1.4) can provide diagnostics of amyloid deposits in the 
brain of patients suffering from Alzheimer’s disease [21]. 
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O
N
N
N
O CH3
CH3
O  
Figure 1.2: Structure of 3-(N, N’-dimethyl-1-(pyridine)pyrrolidine-3-amine)-7-phenoxy-
chromone which is a potential oral-administered obesity suppressor. 
 
N
O CH3
CH3
HO
OH O
OH
 
Figure 1.3: Structure of Rohitukine (5, 7-dihydroxy-2-methyl-8-[4-(3-hydroxy-1-methyl)-
piperininyl]-4-H-1-benzopyran-4-one). 
 
Besides the profoundly diverse biological activities of perimidines, this class of 
heterocyclic compounds and their metal complexes have been widely investigated as 
sensors and fluorescent switches due to their unique fused π-conjugated and non-
conjugated systems [22-25]. For example, the perimidines: 4-(2,3-dihydro-1H-
perimidin-2-yl)-2-methoxyphenol (see Figure 1.5) and 2-(quinoxalin-2-yl)-2, 3-
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dihydro-1H-perimidine showed intense intra-ligand π-π* relaxations in their 
respective emission spectra   [22]. More interestingly, is that only 4-(2,3-dihydro-1H-
perimidin-2-yl)-2-methoxyphenol exhibit solvatochromic effects ascribed to the 
variable degree of hydrogen-bonding between the methoxy group of the perimidine 
compound and the respective solvents used in the study.  Hypothetically, combining 
the biological activities and luminescent properties of 1,3-dihydroperimidine (pm) 
chelators with the radiotherapeutic capabilities of rhenium radionuclides could lead 
to the development of dual diagnostic and therapeutic rhenium 
radiopharmaceuticals. 
 
N
S
NH
CH3
HO
 
Figure 1.4:   Structure of the diagnostic radiopharmaceutical, 11C-radiolabelled Pittsburgh 
compound.  
HN NH
O
OH  
Figure 1.5:   Structure of a photoluminescent perimidine compound, 4-(2,3-dihydro-1H-
perimidin-2-yl)-2-methoxyphenol. 
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1.3 Schiff bases and their d-block metal complexes: 
Tailoring the structural features of Schiff bases has become a simple but effective 
manner to manipulate the properties of the ligands and their transition metal 
complexes. For example, the appended groups connect to the imino bonds can be 
easily altered to influence the catalytic activities of Schiff bases of d-block metal 
complexes, e.g. upon increasing the number of chlorine substituents on the diimine, 
N, N’-bis(hydroxybenzylidene)-1,2-ethylenediamine framework for ruthenium(III) 
complex analogues, the efficiency of electrocatalytic epoxyoxidation of cyclooctene is 
evident from the increased turnover frequencies and current efficiencies of the 
diimine ruthenium(III)-based electrocatalysts [26]. Another advantage of Schiff bases 
as ligand is that biologically relevant moieties can be readily included in the 
framework of Schiff bases [27]. In Figure 1.6, the chromone moieties is integrated in 
the neutral bidentate azo-Schiff bases coordinated to selected first row transition 
metal complexes exhibiting octahedral geometries via the ‘2+2’ coordination modes 
of the two azo-Schiff base chelates and the remaining coordination sites being 
occupied by trans-positioned chloro co-ligands.  Significant to the aforementioned 
research study is that the highly pi-conjugated nature of the chromone-azo-Schiff 
bases allow the latter and its 3d transition metal complexes to produce optimal high 
quantum yields and intense ligand-based fluorescence peaks. 
 
Meticulous design of Schiff bases with the appropriate combinations of donor atoms 
can enforce preferential coordination of Schiff bases to specific metals in various 
oxidation states. In particular, oxovanadium(IV) and dioxovanadium(V) cores have 
been extensively shown to be stabilized by Schiff bases containing a combination of 
hard and soft donor atoms, see Figure 1.7 [28].  Preferential coordination of a 
transition metal in different oxidation states is depicting by the variable coordination 
modes  of the multidentate Schiff base, 2, 6-bis(2-
hydroxyphenyliminomethyl)pyridine (H2dhp) in [Re(dhp)(PPh3)2]I and fac-
[Re(CO)3(H2dhp)Br] where the diimine chelator acts as dianionic N3O2 pentadentate 
and neutral NpyridineNSchiff base ligands, respectively [29]. In rare cases, metal-carbene 
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bonds have been formed through imino carbons; as seen in the paramagnetic 
ruthenium(III) complex, trans-[RuCl(bzp)(PPh3)2] (Hbzp = N-(2-
hydroxybenzylidene)-benzimidazole) [30]. Another factor that influence the 
stabilization of Schiff base metal complexes, is metal chelation, i.e. the position of 
functional groups, donor atoms, mono-imine or higher order imines which 
determines whether constrained or unconstrained bite-angles are formed as well as 
the number of chelate rings within the coordination spheres of the metal complexes.  
 
 
O
O N
M ClCl
N N
OH
CHN
Cl
O
O N
N N
OH
CHN
Cl
 
  Figure 1.6: The general octahedral geometry of the 3d transition metal complexes 
containing neutral chromone-azo-Schiff bases where M = Ni, Co, Zn or Cu. 
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+
 
Figure 1.7:   A tridentate dianionic ONO Schiff base stabilizing the acidic [VO2]+ core. 
 
1.4 Rhenium radiopharmaceuticals: 
1.4.1 Rhenium radionuclides 
Rhenium has two β-emitting isotopes, 186Re, with half-life of 3.77 days and 188Re with 
a relatively stable half-life of 16.9 days. The 186-rhenium radionuclide can be 
produced by neutron irradiation of natural rhenium in a nuclear reactor. However, 
since natural rhenium consists of 185 Re (37.4%) and 187Re (62.6%), this radiochemical 
process leads to considerable impurities. Alternatively, the radionuclide with the 
shorter half-life (viz. 188Re) can be removed by allowing it to decay but this will result 
in considerable loss in activity of the desired isotope (viz. 186Re) [31, 32].   
 
 
185Re + n → 186Re 
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The 188-rhenium radionuclide can be obtained as a solution of 188ReO4 in high 
specific activity from an 188W generator similar in design to the commonly used 
99mTc generator [31]. Such a generator with 0.5 Ci of 188W which has the potential to 
provide therapeutic treatments to several hundred patients over a 2-6 month 
lifetime. The major disadvantage of 188Re for therapeutic applications is the relatively 
short half-life of 17 Hrs [32], which does not impede its applications in treatment of 
metastatic bone cancer, non-resectable liver cancer. 
 
 
188WO42- → 188ReO4- +β 
 
1.4.2 Rhenium radiopharmaceuticals: design approaches and applications 
Several approaches have been employed for the design and applications of rhenium 
radiopharmaceuticals namely the match pair, integrated and bifunctional 
approaches [31, 32]. The match pair approach entails the design of rhenium 
radiopharmaceuticals analogously based on diagnostic 99m-technetium 
radiopharmaceuticals are already well-established. The motivation behind this 
design approach is the fact that rhenium and technetium are group congeners which 
have similar coordination chemistries due to the ‘lanthanide contraction’ which 
ensures that the complexes of the two elements have similar physical characteristics 
(size, lipophilicity, etc). Structurally, they are similar due to the presence of the 
{MI(CO)3}+ (M = Tc, Re). Once such example, is a TcV complex of dimercaptosuccinic 
acid (DMSA) which is used widely as an agent for the imaging of a relatively rare 
medullary thyroid carcinoma. The comparable radiolabelled ReV complex has the 
expected square pyramidal structure with an apical oxo-group and exists as a 
mixture of isomers, see Figure 1.8. Another class of radiopharmaceuticals based on 
186Re and 188Re labelled bearing bisphosphonate hydroxyethylidenephosphonate 
(HEDP) ligands were developed as therapeutic analogues of the 99m-technetium 
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bisphosphonates. They are routinely used for SPECT imaging of bone metastases 
that arise from malignant cancers. The main design flaw in the match pair approach 
is that oxorhenium(V) complexes were notoriously unstable in aqueous media than 
their oxotechnetium(V) counterpart complexes as it undergoes disproportionation 
reaction to afford two rhenium species in oxidation states of +IV and +VII respectively. 
 
S
S S
S
Re
O CO2H
CO2H
HO2C
HO2C  
Figure 1.8: An oxorhenium(V) complex of dimercaptosuccinic acid (DMSA). 
 
Integrated approach involves the manipulation of the metal complex structure to 
meet the topology of a biologically active molecule. An example is a rhenium 
complex which mimics the structure of progesterone, see Figure: 1.9. Alternatively, a 
biological activity moiety can be incorporated in the framework of the organic 
chelator.  
O
O
N
O
S
Re
O
N
O
S
 
Figure 1.9: A structure of oxorhenium(V) complex mimicking the structure of progesterone.  
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The bifunctional approach as the name implies involves the use of a bifunctional 
chelator which can stabilize the metal centre in a specific oxidation state while the 
bifunctional chelator is either directly covalently bonded to a biologically active 
moiety or linked through an organic linker [33].  This design approach provides 
significant improvements in that the biological activity moiety remains unhindered 
electronic properties remain intact allowing it to facilitate biodistribution of the 
radiopharmaceutical. This provides interaction of the biological active moiety with 
targeted growths in the human body. Furthermore, depending on the oxidation state 
of the metal centre, the bifunctional chelator can be designed with the appropriate 
donor atoms.  Recent designs based on the fac-[Re(CO)3]+ core have afforded 
targeting rhenium radiopharmaceuticals for the treatment of bone metastases. One 
of the complexes was tethered to a bifunctional ligand bearing a bisphosphonate 
functional group [34], although it has not undergone clinical trials. Another example 
includes the conjugation of glucosamines to monoanionic NNO-donor multidentate 
chelates coordinated to the fac-[Re(CO)3]+ core, see Figure 1.10 [35].   
 
Re
N
N CO
CO
CO
O
N
H
OH
OH
HO
O
OH
 
Figure 1.10: A facial tricarbonyl rhenium(I) complex with a monoanionic NNO tridentate 
chelator with the bridging amine linker containing glucopyranose moiety.  
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1.5 General chemistry of rhenium(I) and –(V): 
1.5.1 The fac-[ReI(CO)3]+ core 
Alberto et al. were the first to report the synthesis of the rhenium(I) aqua complex, 
fac-[Re(CO)3(H2O)3]+ in a simple one step experimental procedure by the reduction 
Alberto et al. were the first to report the synthesis of the rhenium(I) aqua complex, 
fac-[Re(CO)3(H2O)3]+ in a simple one step experimental procedure by the reduction 
of perrhenate in an aqueous solution of sodium borohydride and in the presence of 
carbon monoxide [8]. Designing radiopharmaceuticals with the metal precursor, fac-
[Re(CO)3(H2O)3]+ exploits the aqueous stability of the metal tricarbonyl core whilst 
manipulating the displacement of the relatively labile water ligands to attach 
pertinent biomolecules to the fac-[ReI(CO)3]+ core. Moreover, a variety of 
multidentate ligand systems have been reacted with the aforementioned facial 
tricarbonyl rhenium(I) triaqua complex cation in all cases they substitute the labile 
aqua co-ligands [36, 37]. 
The fac-[M(CO)3]+{M = Tc or Re} core cations possess several favourable properties 
including: 
 Chemical inertness of the fac-[M(CO)3]+ core due to the low spin d6 
configuration. This provides a convenient platform for in vitro and in vivo 
studies. 
 The small size of the fac-[M(CO)3]+ core allows flexibility and accessibility for 
labelling with various biologically active molecules. 
 The high stability in aqueous media compared to radiopharmaceuticals 
containing the oxorhenium(V) core. The latter is prone to oxidation to [ReO4]- 
by water. 
 
1.5 Oxorhenium(V) core 
Rhenium(V) compounds are generally diamagnetic due to their spin-paired d2 
electronic configuration. These metal complexes have mostly octahedral 
coordination geometry and are stabilized by various metal cores such as the nitride 
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{ReVN}2+ [38], imido {ReVNR}3+, oxo {ReVO}3+ [39]. Among the numerous rhenium(V) 
metal cores, oxorhenium(V) complexes are the most predominant and can undergo 
various reactions: 
 Oxorhenium(V) complexes are normally oxidized by strong oxidants which 
results in the formation of [ReO4]-, without forming any intermediates. For 
example, [ReOCl4(H2O)]- in 10 M HNO3 is oxidized by NO2- to [ReO4]- as 
shown in the following reaction [40, 41]: 
 
5[ReOCl4 (H2O)]- + 2NO2- →  3[ReO4]- + 10HCl + 2[ReOCl5(NO)]- 
 
 Oxorhenium(V) complexes can also undergo reduction as the common route 
to Re(III) complexes, e.g. the reduction of a mono oxorhenium(V) complex by 
triphenylphosphine via the removal of the terminal oxide [42]. In the reaction 
shown below, the terminal oxide is replaced by the solvent molecule CH3CN 
and OPPh3 is the only oxidation by-product. 
 
trans-[ReOCl3(PPh3)2] + CH3CN + PPh3 → trans-[ReCl3(MeCN)(PPh3)2] + OPPh3 
 
 Oxorhenium(V) complexes have shown to readily disproportionate to Re(IV) 
and Re(VI) species, as shown in the chemical reaction below [41]: 
 
3[ReOCl5]2-   + H2O → 3[ReO4] +   2[ReCl6]2-   + Cl + 2HCl 
 
 Ligand substitution is readily affected by conducting coordination reactions 
with stirring at room temperature or by gentle heating in a suitable solvent. 
An example is shown in the following reactions where tetrahydrofuran and 
ethanol produce different products [43]: 
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fac- [ReOCl3(OPPh3)(SMe2)] + Dppen  
THF
 fac- [ReOCl3(Dppen)] + OPPh3  +  
SMe2  
fac- [ReOCl3(OPPh3)(SMe2)] + Dppen
EtOH
fac- [ReOCl2(OEt)(Dppen)] + 
OPPh3  +  SMe2  + HCl 
 
 Formation of rhenium(V) dimers most commonly occurs through the use of 
dioxorhenium(V) precursors but the use of multidentate ligands have also 
shown to be excellent bridging ligands both for the fac-[Re(CO)3]+ and [ReO]3+ 
units in dinuclear compounds. For example, a multiply-bridged dimer (µ-
Cl)(µ-O)(µ-moa)2 [ReIIIReIV(PPh3)]2( H2moa =2-mercapto-orotic acid) was 
isolated when rhenium (V) was used as a precursor [44].                  
 
Coordination chemistry of rhenium (I) and (V): 
1.6.1 Rhenium(I) compounds with bidentate N, X {X = O or N} ligands  
Synergism between the rhenium(I) centre and its facial orientated carbonyl co-
ligands (i.e. sigma metal-to-ligand and corresponding pi-back bonding) affords a 
rigid fac-tricarbonylrhenium(I) unit which implies that there is only three available 
coordination sites that can be manipulated. By far the most rhenium(I) compounds 
have bidentate chelating ligands accompanied with a halide occupying the last 
available coordination site. Furthermore, as rhenium in its oxidation state +I exhibits 
low acidic character balanced by a halide co-ligand, these bidentate ligands typically 
contains neutral donor atoms (e.g.  pyridyl and imino nitrogens).  
This  coordination chemistry of facial tricarbonylrhenium(I) compounds is illustrated 
by its benzo pyrazolylamidino complex (a component obtained from coupling of 3, 
5-dimethylpyrazole with benzonitrile) was successfully coordinated to the 
rhenium(I) core to obtain a bidentate NSchiff baseNBenzonitrile coordination mode, see 
Figure 1.11 [45]. Examples of NO-donor bidentate chelates coordinated fac-
[Re(CO)3]+, include the mononuclear, fac-[Re(CO)3(IPPO)(L)] (L = pyridine or 
dimethylaminopyridine) (IPPOH = 2-(imidazo[1,2-a]pyridin-2-yl)phenol) [see Figure 
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1.12] and the dinuclear, fac-[{Re(CO)3}2(IPPO)2] compounds. The influence of the 
nature of solvents is again emphasized through isolation of aforementioned metal 
compounds given by the fact that the dinuclear compound could only be formed in 
the non-coordinative solvent, toluene [46].  
 
N
N
CH3N
Re
OC
OC
CO
CO
 
Figure 1.11:  Structure of the rhenium(I) complex [X = Br or Cl] with the neutral bidentate 
parazolamidino ligand. 
 
N
N
O
Re
L CO
CO
CO
 
Figure 1.12: General structure of the mononuclear metal complexes,                                   
fac-[Re(CO)3(IPPO)(L)]  where L is pyridine or dimethylaminopyridine. 
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1.6.2 Rhenium(V) complexes with multidentate N-donor ligands 
Displacement of the oxorhenium(V) core requires ligands containing donor atoms 
that can provide enough electron density to stabilize the highly charged rhenium(V) 
centre. For example, ligands containing the amino groups are known to substitute at 
the oxorhenium(V) through single deprotonation to afford Re-NH cores (viz. 
rhenium amido bonds), double deprotonation to form either the [Re=N]3+ bent 
imido or the [Re≡N]3+ linear phenylimido if the lone pair on the nitrogen also gets 
involved in bonding to the metal centre.  
 
Several literature example of linear phenylimido rhenium(V) complexes with aniline 
and 1,2-diaminobenzene have been reported [47-51].  The uracil derivative, 5,6-
diamino-1,3-dimethyluracil (H2ddd) has successfully substituted the dioxo co-
ligands of the metal precursor, cis-[ReO2I(PPh3)2] to form the “2+1” oxofree 
rhenium(V) complex cation, trans-[Re(ddd)(Hddd)I(PPh3)2]+ (see Figure 1.13) where 
the bidentate Hddd six-membered chelate ring is afforded by rhenium-amido and 
rhenium–amino bonds while the ddd monodentate moiety is afforded by the triply 
bonded rhenium imido bond [52]. Later on the condensation of 1, 2-diaminobenzene 
and 5, 6-diamino-1, 3-dimethyluracil with various respective 2-substituted 
aldehydes afforded the corresponding multidentate Schiff bases which readily 
allowed the formation of rhenium-bent imido bonds upon reacting them with 
oxorhenium(V) precursors [53-56]. More specifically, the oxo-free rhenium(V) 
compound was formed from the reaction between cis-[ReVO2I(PPh3)2] and H3duo (N-
(2-hydroxybenzylidene)-5-amino-1,3-dimethyluracil) led to the formation of the 
oxofree, imido compound, trans-[ReV(ddd)(Hduo)(PPh3)2]I [57].  
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Re
Ph3P
I PPh3
NH
N
H2N
N
N
N N
NH2
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O O
H3C CH3
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O
[ReO4]
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Figure 1.13: Structure of a imido, amido, amino oxofree rhenium(V) compound. 
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Chapter 2 
Materials and Methods  
 
2.1 Handling of Rhenium 
Having used non-radioactive rhenium metal precursors in this project, special 
precautions on radioactivity safety were not taken into consideration. In addition, no 
other purification process was carried out on the metal precursors. 
 
2.2 Materials 
2.2.1 Metal precursors 
(a) Ammonium perrhenate 
Ammonium perrhenate (NH4)[ReO4] was obtained from Sigma-Aldrich at +99% 
purity and used without any further purification. 
(b) Rhenium(I) pentacarbonyl bromide 
Rhenium(I) pentacarbonyl bromide, [Re(CO)5Br] was obtained from Sigma-Aldrich 
at 98% purity and used without any further purification. 
(c) Rhenium(I) pentacarbonyl chloride 
Rhenium(I) pentacarbonyl chloride, [Re(CO)5Cl], was obtained from Sigma-Aldrich 
at 98% purity and used without further purification. 
(d) trans-[ReOBr3(PPh3)2][1] 
To a solution of 1.0 g of (NH4)[ReO4] in 3 cm3 concentrated hydrobromic acid, 5.0 g 
of triphenylphosphine in 50 cm3 glacial acetic acid was added. The resultant reaction 
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mixture was stirred for 1 hour at 20oC. A mustard yellow precipitate formed which 
was filtered, washed with glacial acetic acid and diethyl ether and dried under 
vacuum  
 
2.2.2 Solvents and specialized chemicals  
Calf Thymus (CT)-DNA and Phosphate Buffered Saline (PBS) tablets were obtained 
from Sigma Aldrich and used as is. All solvents and common salts were obtained 
from Merck SA. Reagent grade toluene was dried over sodium wire and other 
solvents were used without further purification. 
 
2.2.3 Organic precursors 
All organic precursors and their corresponding percentage impurities are given in 
Table 2.1. These chemicals were obtained from Sigma-Aldrich. 
 
Table 2.1: Organic precursors attained from Sigma-Aldrich. 
Name Purity 
3, 5-Diamino-1,2,4-triazole 99% 
2-Amino-3-formylchromone 97% 
Ethylenediamine 98% 
1,2-Diaminobenzene 99.5% 
1,8-Diaminonaphthalene 99% 
Pyrrole-2-carboxaldehyde 98% 
2 Pyridine carboxaldehyde 99% 
Benzothiazole-2-carboxaldehyde 97% 
 
 
23 
 
 
2.3 Instrumentation: 
The infrared spectra were recorded on a Perkin-Elmer 100 spectrometer in the 4000 – 
450 cm-1 range. The 1H NMR spectra was obtained using Bruker Avance 400 MHz 
spectrometer. All NMR spectra were recorded in deuterated dimethylsulphoxide. 
UV-Vis spectra were recorded using Perkin Elmer Lambda 25. The extinction 
coefficients ( ) are given in dm3.mol-1.cm-1. Melting points were determined using a 
Stuart SMP3 melting point apparatus. The conductivity measurements were 
determined at 295K on a Radiometer R21M127CDM 230 conductivity and pH meter. 
The standard solution of 1M KCl was employed for calibration of the electrode. The 
X-ray data for the metal complexes were recorded on a Bruker Apex Duo equipped 
with an Oxford Instruments Cryojet operating at 100(2) K and an Incoatec 
microsource operating at 30W power. Computational modelling was conducted 
using the Gaussian 09W [2]. The conductivity measurements were determined at 
295K on a Radiometer R21M127CDM 230 conductivity and pH meter. DNA binding 
studies were conducted on a Shimadzu UV-1800 Spectrophotometer coupled with a 
Shimadzu CPS temperature controller.  
 
 
 
 
 
 
 
 
 
24 
 
 
2.4 References 
[1] Johnson, N. P.; Lock, C. J. L.; Wilkinson, G. Inorg. Synth. 9 (1967) 145. 
[2] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. 
Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. 
Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. 
Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. 
Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, 
J.A. Montgomery Jr., J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. 
Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. 
Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. 
Rega, J.M. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. 
Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, 
C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, 
G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, O. 
Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. Fox, GAUSSIAN 09 
(Revision A.01), Gaussian Inc., Wallingford, CT, 2009. 
 
 
 
 
 
 
25 
 
 
Chapter 3 
Formation, Characterization and Computational Studies of 
Mono- and Dinuclear Rhenium(I) Chromone Compounds 
3.1 Introduction 
The considerable attention received by the coordination chemistry of rhenium stems 
from the ideal properties of its 186- and 188-radionuclides which are well suited for 
radiotherapy [1-3]. For example, the bone-targeting therapeutic 
radiopharmaceutical, rhenium-HEDP (HEDP = hydroxyethylidene disphosphonate) 
has several advantages over the commercially available alternatives in terms of 
efficacy, safety and the ability to be produced on site, allowing for rapid treatment of 
patients with painful bone metastases [4]. Furthermore, the facial 
tricarbonylrhenium(I) core has shown to serve as an ideal synthon for the 
formulation of new rhenium radiopharmaceuticals. This is illustrated by the facial 
tricarbonylrhenium(I) complexes stability under physiological conditions where the 
small size of the fac-[Re(CO)3]+ core allows binding to various biological entities [5-
6]. However, the next generation of potential rhenium radiopharmaceuticals requires 
chelators which can stabilize the metal centre both in the low and high oxidation 
states [7]. Furthermore, these multidentate chelators should also cater for the 
inclusion of biologically active moieties which may aid in target specific 
biodistribution of the metallopharmaceuticals [8, 9].  
  
Hence, in this chapter, the coordination susceptibility of multidentate chromone 
ligands towards the facial tricarbonyl rhenium(I) core is described. The rhenium(I) 
complex, fac-[Re(CO)3(chrpychr)Br] (1) was isolated from the equimolar reaction 
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between 2-(4-oxo-4H-chromen-3-yl)-5H-chromeno[2,3-d]pyrimidin-5-one (chrpychr) 
and [Re(CO)5Br]. The coordination reactions of [Re(CO)5Br] with the diimines: N, N‘-
bis((2-amino-3-imino)methylenechromone-1,2-ethane (chret) and N,N’-bis((3-
chromone)methylene)benzene-1,2-diamine (chb) afforded a novel dinuclear 
rhenium(I) compound, fac-(Re(CO)3Br)2(μ-chret) (2) and a mononuclear compound  
fac-[Re(CO)3(bzch)Br] (3) [bzch = 2-benzimidazole-4H-chromen-4-one].  
O
N
N O
O
O
O
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O
O
N N
NH2 H2N
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O
O
O
N N
chb
chret
chrpychr
 
 
Fig. 3.1: structure of ligands chb, chrpychr and chret . 
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3.2 Experimental:  
3.2 Syntheses of ligands 
3.2.1 2-(4-oxo-4H-chromen-3-yl)-5H-chromeno[2,3-d]pyrimidin-5-one (chrpychr) 
The title compound was prepared from the 2:1 molar condensation reaction between 
2-amino-3-formylchromone (0.125 g, 0.660 mmol) and 3,5-diamino-1, 2, 4-triazole 
(0.0327 g, 0.330 mmol) in 15 cm3 of methanol acidified with 3 drops of the 
trifluoroacetic acid. The resultant reaction mixture was heated at reflux temperature 
for 4 hrs. Thereafter, the volume of the reaction mixture was reduced to 10 cm3 on a 
hotplate and placed in an ice-bath to induce the formation of a yellow precipitate 
which was filtered and washed with cold methanol as well as petroleum ether. M.P 
= 170 – 175 ˚C, yield = 32 %. IR (νmax/cm-1): ν(C=O) 1618, 1544 (vs); ν(C=N) 1505, 
1465 (vs); ν(O-C-O) 1417, 1370(s). 1H NMR (295 K/ppm, see Fig. 3.1): 10.08 (s, 1H, 
H23), 9.60 (br, s, 1H, H11), 8.03 (d, 2H, H6, H19), 7.74 (t, 2H, H8, H17), 7.49 – 7.40 (m, 
4H, H7, H9, H16, H18). 
 
3.2.2 N, N‘-bis((2-amino-3-imino)methylenechromone-1,2-ethane (chret) 
The titled diimine was prepared from a 2:1 molar condensation reaction between 2-
amino-3-formylchromone (0.201 g, 1.064 mmol) and ethylene diamine (0.032 g, 0.532 
mmol) in 20 cm3 of absolute ethanol. The reaction mixture was heated until reflux for 
3 hrs and stirred further overnight. Afterwards, the reaction mixture was 
concentrated and cooled in an ice bath to induce precipitation. A yellow precipitate 
was filtered, washed with cold ethanol and petroleum ether. M.P. = 135-140 ˚C, yield 
= 78%. IR (νmax/cm-1): ν(C=O) 1661 (vs); ν(C=N) 1602 (vs); ν(O-C-O) 1451 (s). 1H 
NMR (295 K/ppm, see Fig. 3.3): 10.89 (br, s, 2H, NH2); 8.81 (br, s, 2H, NH2); 8.72 (s, 
2H, H16, H19); 7.98 (dd, 2H, H9, H23, H12, H26); 7.67 (t, 2H, H10, H26); 7.37 (t, 2H, 
H11, H25); 3.83 (s, 4H, H17, H17’, H18, H18’). UV-Vis (DMSO, λmax ( , M-1cm-1)): 327 
nm (sh, 40340); 349 nm (sh, 50240); 363 nm (52080); 397 nm (sh, 24770); 484 (sh, 
20130). 
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3.2.3 N, N’-bis((3-chromone)methylene)benzene-1,2-diamine (chb) 
The diimine, chb was obtained from the condensation reaction of 1,2-
diaminobenzene with a two-fold molar equivalent of 3-formylchromone [10]. 
 
 
Fig. 3.2: 1H NMR spectrum of chrpychr collected in deuterated dimethylsulphoxide. 
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Fig. 3.3: 1H NMR spectrum of chret. The inset shows the aromatic signals between 7.35 and 
8.30 ppm. 
  
3.2.2 Syntheses of metal complexes 
3.2.2.1 fac-[Re(CO)3(chrpychr)] (1) 
A mixture of Re(CO)5Br (0.050 g, 0.123 mmol) and 2-(4-oxo-4H-chromen-3-yl)-5H-
chromeno[2,3-d]pyrimidin-5-one (chrpychr) (0.042 g, 0.123 mmol) in 25 cm3 of 
anhydrous toluene was heated at reflux under nitrogen for 4 hrs. Afterwards, the 
resultant reaction mixture was cooled to room temperature and filtered. An orange 
mother liquor was then left to evaporate slowly at room temperature to afford pale 
orange crystals after 10 days. M.P = 196 – 197 ᴼC; yield = 7.5 %; Conductivity (DMF, 
10-3M) 14.32 ohm. cm2 mol-1; IR (νmax/cm-1): ν(C≡O) 2023, 1919 (sh) and 1894 cm-
1(vs);  ν(C=O) 1608, 1564 (vs); ν(C=N) 1493, 1456 (vs); ν(O-C-O) 1411, 1379(s). 1H 
NMR (295 K /ppm): 10.08 (s, 1H, H23), 9.58 (br, d, 1H, H11), 8.04 (d, 2H, H6, H19), 
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7.75 (t, 2H, H8, H17); 7.49 – 7.40 (m, 4H, H7, H9, H16, H18). UV-Vis (DMF, λmax( , M-
1cm-1)). 291 (29600), 309 (sh, 20100), 355 (57800), 464 (4900). 
 
3.2.2.2 fac-(Re(CO)3Br)2(μ-chret) (2) 
A 1:1 molar reaction of Re(CO)5Br (0.050 g, 0.123 mmol) and chret (0.049 g, 0.123 
mmol) in 15 cm3 of anhydrous toluene was heated until reflux under nitrogen for 4 
hrs. The resultant reaction mixture was cooled to room temperature and filtered. The 
orange precipitate was dried under vacuum while pale orange X-ray quality 
crystalline parallelograms were obtained from layering the precipitate with 1:1 (v:v) 
THF/Hexane over a period of five days. M.P = 215 - 220 ᴼC; yield = 87%; 
Conductivity (DMSO, 10-3M) 16.93 ohm. cm2 mol-1; IR (νmax/cm-1): ν(N-H) 2920, 2850 
(m); ν(C≡O) 2015, 1871 (vs); ν(C=O) 1655 (s); ν(C=N) 1615, 1613 (s); ν(O-C-O) 1504 
and 1464 cm-1 (s) [Figure 3.19]. 1H NMR (295 K /ppm): 10.91 (br, s, 4H, 2x NH2), 8.95 
– 8.65 (m, 6H, H4, H8, H11, H14, H24, H27), 8.12 – 7.11 (m, 4H, H12, H13, H25, H26), 
3.87 (br, s, 4H, H9, H9’, H10, H10’). UV-Vis (DMSO, λmax( , M-1cm-1)): 269 nm (24159); 
296 (sh, 20140); 405 (sh, 2464). 
 
3.2.2.3 fac-[Re(CO)3(bzch)Br] (3) 
The equimolar coordination reaction between [Re(CO)5Br] (0.050 g, 0.123 mmol) and 
chb (0.057 g, 0.123 mmol) in 15 cm3 of anhydrous toluene was heated until reflux 
under nitrogen for 4 hrs. Afterwards, the resultant reaction mixture was cooled to 
room temperature, an orange precipitate was filtered and dried under vacuum.  Pale 
orange cubic crystals suitable for X-ray analysis were obtained from dissolving the 
precipitate in tetrahydrofuran and layering with hexane. M.P = 210 – 211 ᴼC; yield = 
93%; Conductivity (DMSO, 10-3 M): 23.72 ohm.cm2mol-1; IR (νmax/cm-1): ν(N-H) 2915 
(w), ν(C≡O) 2015, 1871 (vs); ν(C=O) 1628, 1607 (s); ν(C=N) 1567 (s); ν(O-C-O) 1482, 
1461. 1H NMR (295 K/ppm): 9.69 (s, 1H, H1); 9.39 (s, 1H, NH); 8.27-7.22 (m, 8H, H3, 
H4, H5, H6, H12, H13, H14, H15). UV-Vis (DMSO, λmax( , M-1 cm-1)): 275 nm (sh, 
26107); 282 nm (27295); 309 (sh, 22025); 394 (6614); 418 (sh, 4394). 
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3.2.2.4 X-Ray Crystallography. 
The X-ray data for 1.C7H8, 2.3(C4H8O) and 3.C7H8 were recorded on a Bruker Apex 
Duo equipped with an Oxford Instruments Cryojet operating at 100(2) K and an 
Incoatec microsource operating at 30W power. Crystal and structure refinement 
data are given in Table 3.1. Selected bond lengths and angles are given in Tables 
3.2 - 3.4, respectively. In all three cases the data were collected with Mo Kα (λ = 
0.71073 Å) radiation at a crystal-to-detector distance of 50 mm. The following 
conditions were used for data collection: omega and phi scans with exposures taken 
at 30 W X-ray power and 0.50º frame widths using APEX2 [11]. The data were 
reduced with the program SAINT [11] using outlier rejection, scan speed scaling, as 
well as standard Lorentz and polarization correction factors. A SADABS semi-
empirical multi-scan absorption correction [12] was applied to the data. Direct 
methods, SHELX-2014 [13] and WinGX [14] were used to solve all three structures. 
All non-hydrogen atoms were located in the difference density map and refined 
anisotropically with SHELX-2014 [13]. All hydrogen atoms were included as 
idealised contributors in the least squares process. Their positions were calculated 
using a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq, 
C-Hmethylene distances of 0.99 Å and Uiso = 1.2 Ueq and C–Hmethyl distances of 0.98 Å and 
Uiso = 1.5 Ueq.   
 
3.2.2.5 Computational details: 
Computational calculations were conducted with GAUSSIAN 09W [15]. Geometry 
optimizations of the metal complexes were achieved through DFT calculations using 
the B3LYP functionals. The 6-311G++ (d, p) basis set was applied to all the C, H, N, O 
and Br and the LANL2DZ basis set, which makes use of effective core potentials was 
applied to the metal centre [16]. Prior to the calculations, the solvent molecules of 
recrystallization for the respective metal complexes were omitted from their crystal 
structures and the resultant structures were used as the starting conformers. Good 
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agreement was found between the optimized and the crystal structures (see Tables 
3.2 - 3.4). Minor deviations are attributed to the fact that gas was optimized- 
structure do not account for non-classical hydrogen bonding interactions nor any 
short distance contacts. Using the optimized structure of the metal complex, did not 
yield values for the frequency calculations. This confirmed that the calculated 
structures are at global minima on their individual potential energy surfaces [17].  
 
3.3 Results and Discussions 
3.3.1 Synthesis, spectral characterization and computational studies of fac-
[Re(CO)3(chrpychr)] (1) 
In an attempt to isolate the diimine, 3, 5-bis-(3-methylimino-chromone)-1H-1, 2, 4-
triazole (prchr) in the presence of trifluoro acetic acid; the free-ligand, chrpychr was 
inadvertently isolated, see proposed mechanism for the formation of chrpychr in 
Scheme 3.1. The 1:1 molar reaction between chrpychr and [Re(CO)5Br] under inert 
conditions led to the formation of the rhenium(I) complex, fac-[Re(CO)3(chrpychr)Br] 
(1) in low yield of 80%. The molar conductivity measurement [14.32 ohm. cm2 mol-1] 
of 1 affirms that it is a non-electrolyte in N, N’-dimethylformamide [18]. 
 
Trifluoroacetic acid has been utilized in numerous molecular transformations 
reactions [19]. In the proposed synthetic route of chrpychr, it is envisaged  
trifluoroacetic acid promotes the deamination of one mole of 2-amino-3-
formylchromone. Subsequently, 3, 5-diamino-1, 2, 4-triazole neutralizes the 
carbocationic form of 3-formylchromone (see Scheme 3.1). Finally, the resultant 3-
formylchromone condenses with the by-product amide ion and the remaining 2-
amino-3-formylchromone to afford 2-(4-oxo-4H-chromen-3-yl)-5H-chromeno[2,3-
d]pyrimidin-5-one (chrpychr). The free-ligand, chrpychr could not be isolated from 
conducting similar reactions without trifluoroacetic acid or 3, 5-diamino-1, 2, 4-
triazole. 
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                    Scheme 3.1: A proposed synthetic route for chrpychr. 
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The IR spectrum of 1 is dominated by the intense vibrational bands of the tricarbonyl 
co-ligands at 2023, 1919 and 1894 cm-1, see Fig. 3.4. The vibrations associated with 
the chrpychr free-ligand and its chelated form in 1 could not be readily assigned due 
to poorly resolved vibrational bands below 1800 cm-1 within the overlay IR spectra 
of 1 and its free-ligand, chrpychr. Hence, computational calculations of 1 at the DFT 
level aided in the identification of the vibrational bands associated with the chrpychr 
chelator [20].  
 
 
 
                    Fig 3.4: Overlay IR spectra of complex 1 and its free-ligand, chrpychr. 
 
 
Notably, the vibration bonds of 1 below 1800 cm-1are found at similar frequencies 
when compared to those of the chrpychr free-ligand below 1800cm-1 which suggests 
that the chrpychr coordinates to rhenium as a neutral chelator, see Fig. 3.5. In the 
calculated IR spectrum of 1, the tri-carbonyl bonds vibrate at 2101, 2023 and 1999 cm-
1. Furthermore, two stretches for each of ν(C=O) [1608, 1564 cm-1 for 1 and 1618, 1544 
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cm-1 for free-ligand], ν(C=N) [1493, 1456 cm-1 for 1 and 1505, 1465 cm-1 for free-
ligand] and ν(O-C-O) [1411, 1379 cm-1 for 1 and 1417, 1370 cm-1 for free-ligand] are 
observed in the experimental IR spectra of 1 and its free-ligand, chrpychr 
respectively. The latter assignments are based on the fact that the IR simulations of 1 
shows that the ketonic [1652 and 1637 cm-1], pyrimidyl C=N [1442 and 1405 cm-1] 
and ether [1318 and 1347 cm-1] bonds predominately vibrate at frequencies similar to 
the corresponding bonds in the experimental spectra. 
 
Fig 3.5: (A) Overlay IR spectra of complex 1 and its free-ligand, chrpychr; (B) calculated IR 
spectrum of complex 1. 
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As indicated in terms of similarities between the IR spectrum of 1 and the free 
ligand, the proton NMR spectrum affirms that the chrpychr ligand coordinates as a 
neutral chelator due to the close similarities between its proton signals of those of 1, 
see Figs. 3.2 and 3.6. For example, the chromone H23 protons resonate at 10.08 ppm 
in the complex as well as the ligand. The same applies to the  phenyl aromatic 
protons. Interestingly, the broad pyrimidyl singlet in the NMR spectrum of chrpychr 
splits into a broad doublet in 1, this is ascribed to long range coupling. Due to, the 
highly delocalized and functionalized nature of the chrpychr numerous intraligand 
π-π* electronic transitions are observed in the UV-Visible spectrum (See Fig. 3.7) 
below 400 nm.  
 
 
Fig. 3.6: 1H NMR spectrum of complex 1 collected in deuterated dimethylsulphoxide. 
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Fig 3.7: Overlay UV/Vis spectra for the free-ligand, chrpychr and complex 1. 
 
3.3.2 Synthesis, spectral characterization and computational studies of 1,2 and 3: 
The compounds:  fac-(Re(CO)3Br)2(μ-chret) (2) and  fac-[Re(CO)3(bzch)Br] (3) [bzch = 
2-benzimidazole-4H-chromen-4-one] were synthesized  under anaerobic conditions 
from the equimolar reaction of [Re(CO)5Br] with the diimines chret and chb, 
respectively. In 2, the chret ligand bridges two fac-[Re(CO)3Br] units while 
coordinating as a bidentate moiety to each metal centre via its NiminoOketo donor sets. 
X-ray structure of 3 (see Fig.3.21) revealed that the chb diimine underwent 
intraligand cyclization followed by the hydrolysis of one of its imine bonds. This 
was despite the anaerobic conditions of the reaction. In fact, the chloro rhenium(I) 
analogue, fac-[Re(CO)3(bzch)Cl] were similarly formed from the reaction of 
[Re(CO)5Cl] with the Schiff base ligand 2-(2- aminophenyliminomethyl)-4H-
chromen-4-one (H2pch) which led to the transformation of the latter to a bzch moiety 
[18].  However, no transformation of the diimine chb occured in the dinuclear 
ruthenium(III) compound, (µ-chb)[mer-RuCl3(PPh3)]2 where the neutral chb moiety 
38 
 
bridges the two cis-[RuIIICl3] cores via its ketonic oxygen and imino nitrogen atoms 
[10].  Furthermore, compounds 1 and 2 exhibit good solubility in high boiling point 
polar solvents including dimethylsulfoxide and dimethylformamide while showing 
a relatively modest solubility in tetrahydrofuran and poor solubility in chlorinated 
solvents such as chloroform. The low molar conductivities [ΛM = 16.93 and 23.72 
ohm.cm2mol-1] of the metallic compounds indicates their neutrality in DMSO.  
 
The close correlation between the optimized and geometrical parameters of the 
respective complexes and the crystal structures is further emphasized by the low 
calculated root-mean-square deviation (RMSD), see Fig. 3.8. However, the somehow 
larger RMSD (0.720A°) of 2 is mainly ascribed to the high degree of largely freedom 
of rotation of the C-C single bonds within the chret chelator. Using the optimized 
structure of the metal complex, the lack of any negative Eigen values in the 
calculated frequencies confirmed that the structures are at global minima on their 
individual potential energy surfaces [17].  
 
Fig. 3.8: Overlay structures of the optimized and crystal structures for 2 and 3 with their 
corresponding RMSD values. The crystal structures are shown in yellow while the optimized 
structures are given in blue. 
 
Broad vibrational bands are observed below 1700 cm-1 in the experimental IR spectra 
of the metal complexes which could not be clearly assigned without the aid of the 
simulated IR spectra of 2 and 3, see Figs. 3.9 – 3.12. Both the experimental [2015, 1871   
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cm-1 for 2 and 3] and simulated [2105, 2018, 2016 cm-1 for 2 and 2097, 2017, 1993 cm-1 
for 3] IR spectra are dominated by the intense stretches of the carbonyl co-ligands. 
Similarly, the ν(N-H) vibrations of 2 and 3 appear as weak intensity vibrational 
bands in their respective simulated [3644 cm-1 for 2 and 3654, 3289 cm-1 for 3] and 
experimental [2920, 2850 cm-1 for 2 and 2915 cm-1 for 3]  IR spectra. The simulated IR 
spectrum of 2 indicates distinctive vibrational bands associated with the ketonic (at 
1687 cm-1), imine (at 1567 cm-1) and ether (at 1469 cm-1) bonds whereas the 
corresponding IR stretching frequencies can be found at 1655 cm-1 [for ν(C=O)], 1464 
cm-1 [for ν(O-C-O)], 1615 and 1613 cm-1 [for ν(C=N)] in the experimental IR spectrum 
of 2. Correlating the simulated IR spectrum of 3 with its experimental IR spectrum, 
revealed that the experimental vibrations for ν(C=O) are found at 1628 and 1607 cm-1 
while the ν(C=N) and ν(O-C-O) appears at 1567 cm-1 and 1461 cm-1, respectively in 
the simulated spectra. 
 
In the proton NMR spectrum of 2, the aliphatic protons of the bridging ethane 
moiety resonates as a singlet at 3.87 ppm, see Fig. 3.13. A broad singlet at 10.91 ppm 
corresponds to the protons of the amino nitrogens of 1 but the analogous protons 
were observed as two broad signals in the proton NMR spectrum of the free-ligand, 
chret, see Fig. 3.1 For 2, the aromatic protons of the chromone moieties and the imino 
signal coalesce into two multiplets (viz. 8.95 – 8.65 ppm and 8.12 – 7.11 ppm) in 
comparison to the corresponding well-resolved signals at 8.72 ppm (for the imino 
protons) and  7.98, 7.67, 7.37 ppm (for the aromatic protons of the chromone 
moieties) of the free-ligand, chret. The most intense signal in the 1H NMR spectrum 
of 3 is due to the H1 proton positioned on the chromone moiety which appears as a 
sharp singlet (at 9.69 ppm).  
 
The benzimidazole proton resonates as an intense signal at 9.39 ppm which 
integrates to one while the multiplet between 8.27 and 7.22 ppm are due to the 
remaining aromatic peaks. The presence of the pi-conjugated neutral chelators in 2 
and 3 results in the occurrence of only intra-ligand π-π* transitions in their UV-Vis 
spectra, see Figs. 3.13 and 3.14. As expected, no metal-based d-d transitions are 
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observed at more red-shifted regions due to the low-spin d6 electron configurations 
of 2 and 3. 
 
Fig 3.9: Overlay IR Spectra of compound 2 and its free-ligand, chret between 400 and 4000 
cm-1. 
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Fig 3.10: Overlay IR Spectra of complex 3 and its free-ligand, chb between 400 and 2000 cm-
1. 
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Fig. 3.11: Comparison between experimental- (A) and simulated (B) spectrum of 2. 
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Fig. 3.12: Comparison between experimental- (A) and simulated (B) spectrum of 3. 
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Fig. 3.13: 1H NMR spectrum of compound 2. 
 
Fig 3.14: Overlay UV/Vis spectra for the free-ligand, chret and compound 2. 
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Fig 3.15: Overlay UV/Vis spectra for the free-ligand, chb and complex 3. 
 
3.3.3 Crystallographic studies  
3.3.3.1 Crystal structure of fac-[Re(CO)3(chrpychr)(Br)] (1) 
X-ray structure analysis revealed that 1 co-crystallized with a toluene molecule in a 
P21/n space group see Fig. 3.17. The crystal lattice is stabilized by a series of 
intramolecular interactions [at 4.034 Å] between the co-planar conventional 
chromone moieties while similar interactions [at 3.674 Å] are found between co-
planar chromone moieties modified with respective annealed pyrimidine rings. The 
intramolecular interactions between the modified chromone moieties are re-enforced 
by pi-stacking interactions [at 3.483 Å] between toluene molecules and the modified 
chromone moieties, see Fig. 3.16. Ultimately, these intermolecular interactions allows 
complex 1 and its solvent molecule of recrystallization to pack in columns aligned 
with the [c]-axis.  
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Complex 1 exhibits a distorted octahedral geometry imposed on by the constrained 
bite angles [O1-Re-N1 = 84.34(6)º] (see Fig. 3.17). Consequently, the angles C1-Re-N1 
[175.01(9)º] and C3-Re-O1 [176.52(9)º] equatorial as well as the axial plane [C2-Re-Br 
= 176.40(8)º] deviate from linearity. The similarity in the bond length of C12-C13 
bond [1.475(4) Å] confirms a bond order of one in the former. Single bond between 
C4-C12 [1.477(4) Å]. The degree of freedom about the C12-C13 allows the chromone 
and pyrimidine annealed chromone moieties to afford a dihedral angle of 12.24º. 
Furthermore, the aforementioned moieties are also found out of the equatorial plane 
ReC1C3O1N1 equatorial plane by 21.78º (wrt the chromone moiety) and 19.81º (wrt 
the annealed pyrimidine annealed chromone moiety).  
 
The difference in the cyclic C-O ether [e.g. C11-O2 = 1.326(3) Å] and C4-O1 [C4-O1 = 
1.257(3) Å] bond lengths affirms that the latter is in the keto-form which is further 
supported by the fact that the Re-O1 [2.137(2) Å] bond distance is identical to an 
analogous bond found in fac-[Re(CO)3(bzch)Cl] [2.137(2) Å] [18]. Evaluation of the 
rhenium to carbonyl bond distances revealed a shorter bond distance for the Re-C3 
bond [1.898(2) Å] when compared to Re-C2 [1.921(5) Å] and Re-C1 [1.918(7) Å] 
bonds. This phenomenon is ascribed to the weaker trans-influence of the ketonic O1 
opposite to the N1 atom and Br co-ligand. The C-N [C23-N1 = 1.347(3) Å, C13-N1 = 
1.366(3) Å C13-N2 = 1.336(3) Å and C14-N2 = 1.317(3) Å] and C-C [C23-C22 = 
1.383(4) Å and C14-C22 = 1.394(3) Å] bond lengths that constitutes the pyrimidine 
ring suggest that the latter is a delocalized π-system and implies that the pyrimidine 
N1 atom acts as a neutral donor to the metal centre. 
  
The rhenium(I) to pyrimidine nitrogen bond length [2.232(2) Å] of 1 is significantly 
higher than the range [2.15(2) – 2.217(9) Å] for analogous bond lengths in other facial 
tricarbonyl rhenium(I) compounds [21-25]. However, in the nitrogen heterocyclic 
carbene rhenium(I) complex, fac-[Re(CO)3(qpim)] (Hqpim = 1-(2-quinoxyl)-3-
phenylimidazolium) [2.621(4) Å]  the Re-Br bond distance is comparable to that of 1 
[Re-Br = 2.6298(2) Å] [25]. 
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Fig. 3.16: A perspective view illustrating the intermolecular interactions between adjacent 
molecules of 1; [A] depicts the intermolecular interactions [at 4.034 Å] between the co-planar 
conventional chromone moieties, [B] depicts the intermolecular [at 3.674 Å] are found 
between co-planar chromone moieties modified with respective annealed pyrimidine rings and 
[C] depicts the pi-stacking interactions [at 3.483 Å] between toluene molecules and the 
modified chromone moieties. 
 
Fig. 3.17: Thermal ellipsoid view of compound 1 showing 50 % probability displacement 
ellipsoids and the atom labelling. 
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3.3.3.2 Crystal structure of fac-(Re(CO)3Br)2(μ-chret) (2) 
Compound 2 co-crystallized with three tetrahydrofuran molecules of 
recrystallization in its triclinic unit cell. The crystal lattice of 2 is stabilized by a 
network of classical intramolecular [Br1···H4a-N4 = 2.73(4) Å and Br2···H2a-N2 = 
2.60(4) Å] and intermolecular hydrogen bonding [O11A···H2b-N2 = 1.95(4) Å and 
O11B···H4b-N4 = 1.91(5) Å], see Fig. 3.18. Collectively these hydrogen bonding 
interactions allows molecules of 2 to pack in columns parallel to the [a]- and [b]-axes.  
 
The geometry at each Re(I) metal centres of 2 are distorted octahedron which is 
largely imposed on by their constrained bite angles [O1-Re1-N1 = 84.48(8)º and N3-
Re2-O6 = 83.91(8)º], see Fig. 3.19. Consequently, the C2-Re1-Br1 [176.84(8)º], O1-Re1-
C3 [177.41(9)º], C1-Re1-N1 [176.2(1)º], Br2-Re2-C6 [177.02(8)º], C4-Re2-O6 [176.4(1)º] 
and N3-Re2-O6 [174.2(1)º] deviate from linearity. The flexibility of the bridging 
ethane moiety affords narrower C=N-C [C18-N3-C19 = 114.7(2)º and C16-N1-C17 =  
114.4(2)º] bond angles than the expected 120º for a bond angle containing a central 
sp2 hybridized nitrogen. Despite the influence of the bridging ethane moiety, the 
imino bond of 2 are in the same range [1.284(3) - 1.301(5) Å] as similar bonds found 
in other Schiff bases [26-29]. Across the respective octahedrons, only the Re1-C2 
[1.897(3) Å] and Re2-C6 [1.897(3) Å] bonds are nearly equidistant which reflects 
similar trans-influence induced on by the Br1 and Br2 atoms, respectively. Hence the 
comparable cis-orientated organometallic bonds [Re1-C1 = 1.941(3) Å, Re1-C3 = 
1.894(3) Å, Re2-C4 = 1.908(3) Å and Re2-C5 = 1.931(5) Å] across the octahedrons in 2 
differs. 
 
The rhenium to ketonic [Re1-O1 = 2.138(2) Å and Re2-O6 = 2.139(2) Å] and imino 
nitrogen [Re1-N1 = 2.170(2) Å and Re2-N3 = 2.168(2) Å] bonds are similar to 
analogous bonds found within fac-[Re(CO)3(chrpychr)Br] [chrpychr = 2-(4-oxo-4H-
chromen-3-yl)-5H-chromeno[2,3-d]pyrimidin-5-one and [(µ-O){ReOCl(amp)}2] [amp 
= 6-amino-3-methyl-1-phenyl-4-azahept-2-ene-1-one] [18, 10]. Bond orders with the 
chret chelator is established based on the ketone bonds [C14-O1 = 1.259(4) Å and 
C28-O1 = 1.261(4) Å] being shorter than the carbonyl bonds [e.g. C1-O3 = 1.145(3) Å] 
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but yet longer than the ether bonds [e.g. C8-O2 = 1.383(3) Å and C21-O7 = 1.346(4) 
Å]. Also, the localized C=C bonds in the chromone moeities remain intact after the 
coordination of the chret chelators as these C=C bonds [C7-C15 = 1.413(4) Å  and 
C17-C18 = 1.414(4) Å] are shorter than the C-C single bond [C17-C18 = 1.536(3) Å] 
that constitutes the bridging ethane moeity. 
 
 
 
Fig. 3.18: A perspective view of 2 illustrating the intramolecular [Br1···H4a-N4 = 2.73(4) Å 
(W) and Br2···H2a-N2 = 2.60(4) Å (Y)] and intermolecular hydrogen bonding 
[O11A···H2b-N2 = 1.95(4) Å (X) and O11B···H4b-N4 (Z)]. 
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Fig. 3.19: Thermal ellipsoid view of compound 2 showing 50 % probability displacement 
ellipsoids and the atom labelling. The tetrahydrofuran molecules of crystallization were 
omitted for clarity. 
 
3.3.3.3 Crystal structure of fac-[Re(CO)3(bzch)Cl] (3) 
Four molecules of 3 occupies the monoclinic unit cell and each of these molecules 
form dimers with molecules of 3 in adjacent unit cells via classical hydrogen-bonding 
interactions [Br1···N2A-H2A/Br1A···N2-H = 2.57(3) Å], see Fig. 3.20. Consequently, 
molecules of 3 are self-assembled in columns aligned with the [b]-axis. Indicative to 
3, the constrained bite angle [O1-Re-N1 = 81.99(7)º] of 3 result in deviation of 
orthogonality in the opposing C1-Re-C3 [86.90(1)º] bond angle, see Fig. 3.21.  
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The rhenium to halide bond of 3 [Re-Br = 2.6322(8) Å] is comparable to those found 
in other facial tricarbonyl rhenium complexes [30, 31, 32]. All the remaining 
coordination bonds of 3 [Re-N1 = 2.186(2) Å, Re-O1 = 2.141(1) Å, Re-C1 = 1.931(2) Å, 
Re-C2 = 1.901(2) Å and Re-C3 = 1.901(2) Å] are similar to its chloro-analogue, fac-
[Re(CO)3(bzch)Cl], viz. Re-Oketone = 2.137(2) Å, Re-Nbenzimidazole = 2.179(2) Å and Re-
Ccarbonyl = 1.929(2) Å, 1.904(2) Å, 1.898(2) Å [26]. Furthermore, the double bond 
character of C10-N1 bonds [1.336(3) Å] are clearly established when compared to the 
C-N bond lengths [C10-N2 = 1.358(3) Å, C16-N1 = 1.401(3) Å and C11-N2 = 1.374(3) 
Å]. In addition, the bridging C9-C10 [1.466(3) Å] bond is single, based on the more 
shorter localized C=C [1.365(3) Å] chromone bond. In turn, the degree of freedom 
around the C9-10 single bond allows the chromone and benzimidazole plane to form 
a dihedral angle of 6.01º. Also, the benzimidazole  and chromone moeities lies out of 
the plane of the O1N1C3C1 mean equotorial plane by 17.83º and 18.37º, respectively. 
The toluene molecule of recrystallization from an adjacent unit cell is nearly co-
planar with the bzch chelator of 3 indicating π-π interactions between this toluene 
molecule and the bzch chelator. 
 
Fig. 3.20: A perspective view of the dimer of 3 formed by hydrogen bonding interactions: 
Br1···N2A-H2A/Br_A···N2-H2 = 2.57(3) Å. 
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Fig. 3.21: Thermal ellipsoid view of complex 3 showing 50 % probability displacement 
ellipsoids and the atom labelling. The toluene molecule of crystallization were omitted for 
clarity. 
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Table 3.1: Crystal data and structure refinement data. 
 1.C7H8 2.3(C4H8O) 3.C7H8 
Empirical Formula C23H10BrN2O7Re.C
7H8 
C28H18Br2N4O10Re2.3(C4
H8O) 
C19H10BrN2O5Re.C
7H8 
Formula weight 783.98 1318.99 704.53 
Temperature/K 100(2) 100(2) 100(2) 
Crystal system Monoclinic Triclinic Monoclinic 
Space group P21/n P-1 P21/n 
Unit cell dimensions (Ǻ, 
°) 
a = 12.1814(5) a = 1.28859(6) a = 12.400(5) 
 b = 13.3633(6) b = 13.1199(6) b = 11.778(5) 
 c = 16.5656(7) Å c = 14.9558(7) c = 16.316(5) 
 α = 90.000(5) α= 114.601(2) α = 90.000(5) 
 β = 106.087(2)° β = 98.138(2) β = 92.469(5) 
 γ = 90.000(5) γ = 102.350(2) γ = 90.000(5) 
Crystal size (mm) 0.28 x 0.09 x 0.03 0.13 x 0.06 x 0.05 0.09 x 0.06 x 0.05 
V(Å3) 2591.02(19)  2168.73 (18) 2380.07(16) 
Z 4 2 4 
Density (calc.) (Mg/m3) 2.011  2.020 1.966 
Absorption coefficient 
(mm-1) 
6.29  7.49 6.82 
F(000) 1512 1268 1352 
θ range for data 
collection (deg) 
1.9; 26.1 1.6; 29.1 2.0; 29.0 
Reflections measured 47342 41497 23824 
Observed reflections 
[I>2σ(I)] 
5015 10414 6310 
Independent reflections 4526 11421 5621 
Data/Restraints/param
eters 
4526/0/371 11421/0/566 5621/0/321 
Goodness of fit on F2 1.048 1.03 1.03 
Observed R, wR2  0.016; 0.033 0.018; 0.043 0.020; 0.042 
Rint 0.033 0.018 0.027 
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Table 3.2: Comparison between the experimental and calculated bond lengths (Å) and angles 
(ᴼ) for 1. 
 Experimental Calculated 
Re-Br 2.6298(2) 2.65898 
Re-O1 2.137(2) 2.17665 
Re-N1 2.232(2) 2.27053 
Re-C1 1.919(3) 1.92163 
Re-C2 1.922(2) 1.91026 
Re-C3 1.898(2) 1.91700 
C12-C13 1.477(4) 1.48402 
C11-O2 1.326(3) 1.32891 
C4-O1 1.257(3) 1.24257 
C23-N1 1.347(3) 1.34122 
C13-N1 1.366(3) 1.36268 
C13-N2 1.336(3) 1.33356 
C14-N2 1.317(3) 1.31771 
C23-C22 1.383(4) 1.38653 
C14-C22 1.394(3) 1.39898 
O1-Re-N1 84.34(6) 81.970 
C1-Re-N1 175.01(9) 173.596 
C3-Re-O1 176.52(9) 175.589 
C2-Re-Br 176.40(8) 175.042 
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Table 3.3: Selected bond lengths [Å] and bond angles [°] for 2. 
 Experimental Optimized 
Re1-Br1 2.6455(3) 2.72064 
Re2-Br2 2.6377(3) 2.72059 
Re1-O1 2.137(2) 2.1765 
Re2-O6 2.139(2) 2.1764 
Re1-N1 2.169(2) 2.2224 
Re2-N3 2.171(2) 2.2224 
Re1-C1 1.942(3) 1.9344 
Re1-C2 1.894(3) 1.9091 
Re1-C3 1.897(3) 1.9071 
Re2-C4 1.908(3) 1.9071 
Re2-C5 1.932(3) 1.9091 
Re2-C6 1.893(2) 1.9343 
C16-N1 1.286(4) 1.2919 
C19-N3 1.291(4) 1.2919 
C14-O1 1.259(4) 1.2502 
C28-O6 1.261(3) 1.2503 
C1-O3 1.144(3) 1.1492 
C8-O2 1.383(3) 1.3796 
C21-O7 1.347(4) 1.3440 
C7-C15 1.414(4) 1.4102 
C20-C21 1.411(4) 1.4103 
C17-C18 1.537(3) 1.5374 
O1-Re1-N1 84.52(7) 83.027 
O6-Re2-O6 83.93(7) 83.023 
C2-Re1-Br1 176.85(8) 177.228 
O1-Re1-C3 177.41(9) 176.550 
C1-Re1-N1 176.2(1) 174.310 
Br2-Re2-C6 176.99(8) 177.236 
C4-Re2-O6 176.41(9) 176.545 
N3-Re2-C5 174.2(1) 174.309 
C16-N1-C11 115.0(2) 114.920 
C18-N3-C19 114.8(2) 114.920 
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Table 3.4: Selected bond lengths [Å] and bond angles [°] for 3. 
 Experimental  Optimized 
Re-Br 2.6322(8) 2.66556 
Re-N1 2.186(2) 2.3072 
Re-O1 2.141(2) 2.2226 
Re-C1 1.931(2) 1.9263 
Re-C2 1.901(2) 1.9150 
Re-C3 1.901(2) 1.9034 
C9-C10 1.466(3) 1.4608 
C1-C9 1.365(3) 1.3601 
O1-Re-N1 81.99(7) 80.800 
C1-Re-C3 86.90(1) 88.380 
Br-Re-C2 175.82(7) 176.266 
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Chapter 4 
Coordination behaviours of Perimidine ligands incorporating 
fused N-donor heterocyclics towards Rhenium(I) and –(V) 
 
4.1 Introduction: 
Effective treatment of cancer and neurodegenerative diseases like Alzheimer’s 
disease by radio-therapeutics requires non-invasive treatment of tumours and 
amyloidal plaques, respectively [1-2]. Rhenium radiopharmaceuticals might be a 
plausible alternative to physical removal of tumours or amyloidal plaques since the 
186- and 188-rhenium radionuclides have optimal half-lives and beta-max energies 
suitable for the treatment of large (17 hrs and 2.10 MeV for the 188Re radionuclide) 
and small (90 hrs and 1.07 MeV for 186Re radionuclide) growths in the body [3]. 
Furthermore, rhenium exhibits stability in various oxidation states accompanied 
with rich coordination chemistry to several ligand systems containing combinations 
of numerous donor atoms [4]. In addition, the applied radiochemistry of rhenium is 
well developed for the production of the rhenium radionuclides and their 
subsequent utilization in radio-labelling to ligands [5].  
 
However, the fundamental coordination chemistry of rhenium still has a pivotal role 
to play in designing functional rhenium radiopharmaceuticals as current trends 
involve exploring the coordination susceptibility of biologically relevant ligands 
towards the [ReVO]3+ and fac-[ReI(CO)3]+ cores [6-7]. The biological entities within 
these classes of ligands can potentially facilitate the metal complex in exhibiting a 
target-specific biodistribution. Examples of this design strategy include rhenium 
complexes which are analogues of the Pittsburgh Compound B (2-(4-
methylaminophenyl)-6-hydroxybenzothiazole)). The coordinated benzothiazole 
chelators induce the rhenium complexes to selectively target amyloidal plaques in 
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the brain [8]. Furthermore, the chelation of design ligands stabilizes the metalo 
complexes when compared  to metal complexes with monodentate ligands under in 
vivo conditions [9]. In addition, interactions of the rhenium complex with DNA of 
cancerous tumours are also essential for a defined biodistribution patterns of the 
metallo drug and this factor is influenced mainly by electronic properties of the 
chelator [10]. 
 
We conducted the coordination reactions of the perimidine ligands incorporating 
fused N-donor heterocyclics:  2-(benzothiazole)-2,3-dihydro-1H-perimidine (bzpm) 
and 2,3-dihydro-2-(pyridine)-1H-perimidine (pypm) with [Re(CO)5Br]  as well as 2,3-
dihydro-2-(1H-pyrrole)-1H-perimidine (pyrpm) with trans-[ReOBr3(PPh3)3] to afford  
fac-[Re(CO)3(bzpm)Br] (1), fac-[Re(CO)3(pypm)Br] (2) and cis-[Re(pyrnp)Br2(PPh3)] 
(3) {H3pyrnp = 8-((1H-pyrrole)iminomethyl)naphthalene-1-amine}, respectively. The 
interest in these ligands stems from the various biological activities of the respective 
fused heterocyclic moeities and the perimidine core. More specifically, derivatives of 
the benzothiazole, pyridine or pyrrole moeities have shown to exhibit anticancer 
activities against various cancer cell lines while perimidine-derived compounds 
have been the leading candidates anti-(microbial/antifungal/cancer) agents, e.g. the 
Pd(II) complex of the perimidine ligand, 2-(2-thienyl)-2,3-dihydro-1H-perimidine 
and its free-ligand have shown antimicrobial activities against a series of microbes 
[11-16]. Furthermore, the Pd metal complexes were validated by the X-ray diffraction 
analysis structures of the metal complexes. The DNA binding capabilities of the 
metal complexes were evaluated by UV-Vis titrations with Calf Thymus (CT)-DNA. 
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4.2   Experimental 
4.2.1 Syntheses of ligands 
4.2.1.1 2-(benzothiazole)-2,3-dihydro-1H-perimidine (bzpm) 
The titled compound was prepared from a 1:1 molar condensation reaction between 
benzothiazole-2-carboxaldehyde (0.1928 g, 1.182 mmol) and 1, 8-
diaminonaphthalene (0.187 g, 1.182 mmol) in 20 cm3 of absolute ethanol. The catalyst 
employed was AlCl3.6H2O (0.028 g, 0.118 mmol). The resultant reaction mixture was 
heated until reflux for 24 hrs. Afterwards, the volume of a dark brown solution was 
reduced using a rotary-evaporator and a dark brown precipitate was filtered off. 
This precipitate was purified via column chromatography using a 6:4 (v:v) ethyl 
acetate:hexane solvent system to produce a brown  precipitate. M.P. = 205 – 206.5 ˚C, 
yield = 70%. IR (νmax/cm-1):  ν(N-H) 3442, 3307 (m); ν(C=N) 1595 (s). 1H NMR (295K/ 
ppm, see Fig. 4.1): 8.03 – 7.92 (m, 2H, H5, H8); 7.49 (t, 2H, H6, H7); 7.45 – 7.33 (m, 2H, 
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H14, H18); 7.06 (d, 2H, H13, H19); 6.61 (d, 2H, N2H, N3H); 5.93 (s, 1H, H11). UV-vis 
(DCM, (λmax (ε, M-1cm-1))): 316 nm (7874); 338 nm (sh, 7548); 393 nm (sh, 2461). 
 
 
Fig. 4.1: 1H NMR spectrum of the free-ligand, bzpm. 
4.2.1.2 2,3-dihydro-2-(pyridine)-1H-perimidine (pypm) 
A 1:1 molar condensation reaction between 2-pyridinecarboxaldehyde (0.404 g, 3.774 
mmol) and 1, 8-diaminonaphthalene (0.597 g, 3.774 mmol) was conducted in 20 cm3 
of absolute ethanol. A catalytic amount of AlCl3.6H2O (0.091 g, 0.377 mmol) of the 
molarity was added to the reaction vessel. Then the reaction mixture was heated 
until reflux for 24 hrs. Afterwards, the volume of the reaction mixture was reduced 
using a rotary-evaporator to afford a brick-red precipitate. This precipitate was 
purified via column chromatography using a 6:4 (v:v) ethyl acetate:hexane solvent 
system to produce a brown precipitate. M.P. = 155-156.4 ˚C, yield = 67.5%. IR 
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(νmax/cm-1): ν(N-H) 3173, 3047 (m), ν(C=N) 1596 (vs). 1H NMR (295 K/ppm, see Fig. 
4.2): 8.60 (d, 1H, H16); 7.83 (t, 2H, H17, H18); 7.59 (d, 1H, H19); 7.41 – 7.34 (t, 2H, H7, 
H11); 6.99 (d, 2H, H8, H10); 6.92 (br, s, 2H, N1H, N2H); 5.48 (s, 1H, H14). UV-vis 
(DCM, (λmax (ε, M-1cm-1))): 338 nm (sh, 17274), 353 nm (19362). 
 
Fig. 4.2: 1H NMR spectrum of the free-ligand, pypm. 
 
4.2.1.3 2,3-dihydro-2-(1H-pyrrole)-1H-perimidine (pyrpm) 
Equimolar amounts of pyrrole-2-carboxaldehyde (0.100 g, 1.490 mmol), and 1, 8-
diaminonaphthalene (0.235 g, 1.490 mmol) was dissolved in 20 cm3 of absolute 
ethanol. The catalyst employed was AlCl3.6H2O (0.035 g, 0.149 mmol). The resultant 
reaction mixture was heated until reflux for 24 hrs. Afterwards, the reaction mixture 
was reduced using rotary-evaporator and a dark brown precipitate was filtered-off. 
This precipitate was purified via column chromatography using silica as the 
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stationary phase and a 6:4 (v:v) ethyl acetate :hexane solvent system to produce a 
brown compound. M.P. = 150.2-152.6 ˚C, yield = 77%. IR (νmax/cm-1): ν(N-H)pyrrole 
3331 (br, s);  ν(N-H)perimidine 3130, 3041 (m). 1H NMR (295 K /ppm): 7.29-7.24 (m, 1H, 
H1); 7.15 (t, 2H, H8, H12); 6.98 (d, 2H, H9, H11); 6.79-6.73 (m, 1H, H2); 6.50 (s, br, 2H, 
N2H, N3H); 6.03-5.98 (s, 1H, H5). UV-vis (DCM, (λmax (ε, M-1cm-1))): 342 nm (sh, 
17812), 353 nm (18504). 
 
Fig. 4.3: 1H NMR spectrum of pyrpm. 
 
4.2.2 Syntheses of metal complexes 
4.2.2.1 fac-[Re(CO)3(bzpm)Br] (1) 
A 1:1 molar reaction mixture between [Re(CO)5Br] (0.016 g, 0.038 mmol) and bzpm 
(0.013 g, 0.038 mmol) in 15 cm3 of anhydrous toluene was heated until reflux under 
nitrogen for 4 hrs. The resultant reaction mixture was cooled to room temperature 
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and filtered. A dark brown precipitate was collected and dried under vacuum. Dark 
brown cubic crystals were obtained from layering the precipitate with 1:1 (v:v) 
THF/Hexane over a period of five days. M.P = 220-221 °C; yield = 89.9%; 
Conductivity (DMSO, 10-3M) 23.72 ohm. cm2 mol-1; IR (νmax/cm-1): ν(N-H) 3312, 3146 
cm-1 (m); ν(C≡O) 2020, 1895 (vs); ν(C=N) 1604 (s). 1H NMR (295 K/ppm, see Fig. 4.4): 
8.63 (br, s, 1H, N2H); 8.43 (d, 1H, H8); 8.18 (d, 1H, H5); 8.04-6.71 (m, 7H, H6, H7, H13, 
H14, H15, H17, H18); 6.56 (d, 1H, H19); 6.33 (d, 1H, N3H); 5.90 (d, 1H, H11). UV-Vis 
(DMSO, λmax ( , M-1cm-1) 319 nm (9336); 339 nm (sh, 8676). 
 
Fig. 4.4: 1H NMR spectrum of complex 1. 
 
4.2.2.2 fac-[Re(CO)3(pypm)Br] (2) 
The titled metal complex was isolated from the coordination reaction of [Re(CO)5Br] 
(0.029 g, 0.073 mmol) with pypm (0.018 g, 0.073 mmol) in 15 cm3 of anhydrous 
toluene was heated until reflux under nitrogen for 4 hrs. The resultant reaction 
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mixture was cooled to room temperature and filtered. A brick-red precipitate was 
collected and dried under vacuum.  X-ray quality brick-red crystals were obtained 
from layering the precipitate with 1:1 (v:v) THF/Hexane over a period of five days. 
M.P = 190-200 ᴼC; yield = 87%; Conductivity (DMSO, 10-3M) 24.38 ohm.cm2mol-1; IR 
(νmax/cm-1): ν(N-H) 3295, 3210 cm-1 (m); ν(C≡O) 2019, 1888 (vs); ν(C=N) 1605 (s). 1H 
NMR (295 K/ppm, see Fig. 4.5): 11.84 (br, s, N1H); 9.15 (d, 1H, H16); 8.89 (d, 1H, 
H19); 8.69 (d, 1H, H12); 8.47 (t, 1H, H17); 8.13 (br, s, 1H, H10); 8.08 (d, 1H, H8); 7.91 (t, 
1H, H11); 7.74 (t, 1H, H7); 7.61 (d, 1H, H6)..UV-Vis (DMSO, λmax ( , M-1cm-1)) 336 nm 
(37667); 393 nm (sh, 20963); 534 (sh, 3937). 
 
Fig. 4.5: 1H NMR spectrum of complex 2. 
 
4.2.2.3 cis-[Re(pyrnp)Br2(PPh3)] (3)  
The equimolar reaction mixture of trans-[ReOBr3(PPh3)2]  (0.050 g, 0.052 mmol) and 
pyrpm (0.012 g, 0.052 mmol) in 15 cm3 of anhydrous toluene was heated until reflux 
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for 4 hrs. The resultant reaction mixture was cooled to room temperature and 
filtered. The mother liquor was allowed to undergo slow evaporation and dark 
brown parallelogram XRD quality crystals were obtained after 10 days. M.P = 200-
205 ᴼC; yield = 80%; Conductivity (DMSO, 10-3M) 24.95 ohm.cm2mol-1; IR (νmax/cm-
1): ν(C=N)Schiff base 1576 (s); ν(C=N)pyrrole 1480 (m); ν(Re-N) 1116 (vs).  1H NMR (295 K 
/ppm, see Fig. 4.6): 8.30 (d, 1H, H1); 8.16 (s, 1H, H5); 8.08 (d, 1H, H3); 7.80 (t, 1H, 
H2); 7.70-7.53 (m, 15H, PPh3); 7.46-7.12 (m, 6H, H7, H8, H9, H11, H12, H13). UV-Vis 
(DMSO, λmax ( , M-1cm-1)) 279 nm (17941); 285 nm (18490); 311 nm (sh, 15280); 397 nm 
(sh, 3734); 420 nm (sh, 2637). 
 
Fig. 4.6: 1H NMR spectrum of complex 3. 
 
4.2.3 X-ray diffraction 
The X-ray data for the metal complexes were recorded on a Bruker Apex Duo 
equipped with an Oxford Instruments Cryojet operating at 100(2) K and an Incoatec 
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microsource operating at 30 W power. Selected bond lengths and angles are given 
in Tables 2, 3 and 4, respectively. In all three cases the data were collected with 
MoKα (λ = 0.71073 Å) radiation at a crystal-to-detector distance of 50 mm. The 
following conditions were used for data collection: omega and phi scans with 
exposures taken at 30 W X-ray power and 0.50º frame widths using APEX2 [17]. The 
data were reduced with the program SAINT [17] using outlier rejection, scan speed 
scaling, as well as standard Lorentz and polarization correction factors. A SADABS 
semi-empirical multi-scan absorption correction [18] was applied to the data. Direct 
methods, SHELX-2014 [19] and WinGX [20] were used to solve all three structures. 
All non-hydrogen atoms were located in the difference density map and refined 
anisotropically with SHELX-2014 [19]. All hydrogen atoms were included as 
idealised contributors in the least squares process. Their positions were calculated 
using a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq, 
C-Hmethylene distances of 0.99 Å and Uiso = 1.2 Ueq and C–Hmethyl distances of 0.98 Å and 
Uiso = 1.5 Ueq.  
 
4.3 DNA Binding Studies 
UV-Vis spectroscopic titrations were conducted using metal complex 1 or 2 and CT-
DNA. The concentration of the metal complexes was 1 mM prepared in DMSO while 
the CT-DNA stock solution was prepared in a pH 7.4 PBS buffer solution prepared 
in ultrapure water. The DNA concentration per nucleotide base pair of the CT-DNA 
stock solution was determined using the absorption coefficient of the CT-DNA (ɛ260 = 
6600 M-1 cm-1). The CT-DNA stock solution was incubated at 25 °C over a period of 
24 hrs.  
 
The DNA titrations were conducting by adding (0 – 100 μl) incremental amount of 
CT-DNA (in pH 7.4 PBS buffer) to the sample cell containing 1 mM solutions of the 
respective metal complexes. The same volume of CT-DNA (in pH 7.4 PBS buffer) 
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was added stepwise in the reference cell to cancel out any absorptions associated 
with the CT-DNA. Prior to any UV-Vis measurements and each CT-DNA aliquot 
addition, a 3 minute incubation period was allowed during which the metallic 
compound and CT-DNA was homogeneously mixed. 
 
4.4 Results and Discussion 
4.4.1 Synthesis and spectral characterization 
The rhenium compounds:  fac-[Re(CO)3(bzpm)Br](1), fac-[Re(CO)3(pypm)Br](2) and 
cis-[Re(pyrnp)Br2(PPh3)](3) were synthesized under anaerobic conditions in good 
yields from the coordination reactions of [Re(CO)5Br] with bzpm, pypm and pyrpm, 
respectively. These metal complexes exhibit good solubility in high boiling point 
polar solvents including dimethylsulfoxide and dimethylformamide but they are 
moderately soluble in tetrahydrofuran and toluene. In addition, poor solubility was 
observed in chlorinated solvents such as chloroform.  
 
For 1 and 2, bzpm and pypm moieties act respectively as neutral bidentate chelators 
via their NperimidineNbenzothiazole and NperimidineNpyridine donor sets. For the formation of the 
oxo-free rhenium(V) complex 3, the more acidic character of the rhenium(V) centre 
induced ring-opening of the central pyrimidine ring of pyrpm free-ligand which 
resulted in the coordination of the tridentate trianionic pyrpn Schiff base chelator. 
The low molar conductivity values of the metal complexes 1 - 3 are comparable to 
other neutral rhenium compounds in dimethylsulphoxide [21]. 
 
The IR spectra of 1 (at 2020 and 1895 cm-1) and 2 (at 2019 and 1888 cm-1) show intense 
vibrational bands indicative of rhenium(I) compounds that contain carbonyl co-
ligands in facial orientations, see Fig. 4.7 and 4.8. Complex 3 is an oxo-free 
rhenium(V) complex based on the absence of Re=O stretch which is theoretically 
expected between 950 and 1000 cm-1 [22-25] contrasted by presence of a strong 
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bending frequency of rhenium(V)-imido bond, ν(Re=N) between 1050 and 1100 cm-1 
[26-29].  Furthermore, for 3, the disappearance of the three ν(N-H) vibrations 
originally found in the IR spectrum of the free-ligand, pyrpm (at 3331, 3130 and 3041 
cm-1) suggest that perimidine and pyrrole N-H protons of the pyrpn chelator (of 3) 
have been deprotonated, see Fig. 4.9. In addition, the occurrence of the 
distinguishable C=N imine and pyrrole stretches in the IR spectrum of 3 suggests the 
ring-opening transformation of the free-ligand, pyrpm to the Schiff base chelator, 
pyrpn. In the case of 1 and 2 where their respective chelators are neutral; similar 
free-ligand [ν(N-H) at 3442, 3307 cm-1; ν(C=N) at 1695 cm-1 for bzpm and ν(N-H) 
3173, 3047 cm-1; ν(C=N) 1596 cm-1 for pypm] and chelator [ν(N-H) at 3312, 3146 cm-1; 
ν(C=N) at 1604 cm-1 for 1 and ν(N-H) at 3295, 3210 cm-1; ν(C=N) at 1605 cm-1 for 2] 
vibrations are found within the IR spectra of the free-ligands (for bzpm and pypm) 
and their respective metal complexes 1 and 2. 
 
The coordination of the chelator, bzpm to rhenium in 1 is confirmed by the  
coalescence of the aromatic signals for the chelator in the complex in contrast to its 
well-resolved signals observed in the free-ligand form. Further confirmation is 
comes from the splitting of the doublet of perimidine N-H signals (found in the 
NMR spectrum of the free-ligand) into two singlets at 8.63 (for N2H) and 6.33 (for 
N3H) ppm found in the IR spectrum of the 1. Notably, in the proton NMR spectrum 
of 2 is the disappearance of one of the perimidyl nitrogen protons while the 
remaining N-H signal (for N1H) resonating at a significantly downfield position in 
comparison to the broad singlet observed at 6.92  ppm (for N1H and N2H) in the 
proton spectrum for the free-ligand, pypm. In fact, the X-ray crystal structure of 2 
corroborates the missing perimidyl nitrogen proton as well as the H14 atom (see 
Section 4.4.3) .  In Fig. 4.5 aromatic signals of 2 are in the form d:d:d:t:s:d:t:t:d where 
each signal integrates to one. The proton NMR spectrum of 3 (Fig. 4.6) is dominated 
by the intense multiplet (between 7.70 and 7.53 ppm) of the triphenylphosphine co-
ligand. In comparison to the NMR spectrum of the free-ligand, pyrpm, no pyrrole 
and pyrimidyl N-H signals are observed in the NMR spectrum of 3. The H5 signal is 
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shifted significantly downfield to 8.16 ppm. These observations emphasize the 
distinctive structural differences between the free-ligand, pyrpm and its chelator 
form, pyrpn.   
 
 
Fig 4.7: Overlay IR spectra for bzpm and its metal complex 1 between 380 and 2200 cm-1. 
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Fig 4.8: Overlay IR spectra for, pypm and its metal complex 2 between 380 and 2200 cm-1. 
 
Fig. 4.9: Overlay IR spectra for pyrpm and its metal complex 3 between 380 and 2000 cm-1. 
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The electronic spectra of the free ligands and metal complexes spots numerous 
common intra-ligand π-π* transitions below 400 nm. The more red-shifted electronic 
transitions are ascribed to metal-to-ligand (for 1 and 2) (see Figs. 4.10 and 4.11) and 
ligand-to-metal (for 3) (see Fig. 4.12) charge transfer bands. The absence of the 
expected metal-based d-d electronic transition for the rhenium(V) complex indicates 
that the presence of the pyrpn chelator increases the band-gap energy of 3, which 
makes the metal-based electronic transition unfavourable. 
 
Fig. 4.10: Overlay UV-Vis spectra of 1 and its free-ligand, bzpm. 
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Fig 4.11: Overlay UV/Vis spectra for pypm and complex 2. 
 
Fig 4.12: Overlay UV/Vis spectra for pyrpm and complex 3. 
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4.4.2 DNA Binding Studies 
UV-Visible molecular is an effective tool for determining the binding mode of metal 
to DNA including quantifying the metal complex to DNA interaction.  This is 
achieved by calculating the intrinsic binding constants (Kb) of the metal complex 
[30]. The intrinsic binding constants (Kb) of 1 and 2 were calculated using equation 
(A) by monitoring the change in absorbance values of some selected π-π* intraligand 
electronic transitions at 333 nm (for 1) and 335 nm (for 2): 
 
[DNA]/(ɛa-ɛf) = [DNA]/( ɛa-ɛf) + Kb(ɛb-ɛf)                               A 
 
where [DNA] is the concentration of the molar DNA in base pairs, ɛa is the extinction 
coefficient of the observed absorbance value at the given DNA concentration, ɛf is the 
extinction coefficient of the complex free in solution and ɛb is the extinction 
coefficient of the complex when fully bound to the DNA. A plot of [DNA]/(ɛa-ɛf) 
versus [DNA] gives a slope 1/[ɛa-ɛf] and the Y-intercept equals 1/Kb(ɛb-ɛf). The 
intrinsic binding constant Kb is the ratio of the slope to the Y–intercept [31].  
 
Progressive decreases in the absorbance values of the intra-ligand electronic 
transitions accompanied with no significant stock shifts suggest the chelators are 
partially intercalated between the base pairs of the CT-DNA, see Figs. 4.13 and 4.14. 
In fact, these hypochromic effects are synonomous with many rhenium(I) 
compounds containing pi-conjugated chelators [31, 32]. This is further supported by 
the fact that the calculated intrinsic binding constants of 1 (4.1 x 105 M-1) and 2 (1.4 x 
105 M-1) are either within or close to the range [1.5 x 105 - 1.32 x 107 M-1] of other 
rhenium(I) complexes that are classed as DNA interchelators and which exhibit 
hypochromism [32-34]. However for complex 3, due to the presence of the bulky 
triphenylphosphine co-ligand, negligible change was noticed when the electronic 
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spectroscopy titrations. The triphenylphosphine co-ligand hindering DNA 
intercalation or groove binding of this metal complex to DNA.  
 
Fig. 4.13: Overlay UV-Vis spectra of the CT-DNA (in pH 7.4 PBS buffer) titrations 
conducted with metal complex 1. The UV-Vis spectrum with the dashed line is the initial 
spectrum without any CT-DNA added. The inset shows the plot of [DNA]/(ɛa-ɛf) x 1010 vs 
[DNA] x 105 and its linear trend line. 
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Fig. 4.14: Overlay UV-Vis spectra of the CT-DNA titrations (in pH 7.4 PBS buffer) 
conducted with metal complex 2. The UV-Vis spectrum with the dashed line is the initial 
spectrum without any CT-DNA added. The inset shows the plot of [DNA]/(ɛa-ɛf) x 1010 vs 
[DNA] x 105 and its linear trend line. 
 
4.4 Crystallographic studies 
Two monomers of 1 occupies its triclinic unit cell and each monomer forms dimers 
with another monomer in adjacent unit cell via classical hydrogen bonding 
interactions [N3-H3···BrA/N3A-H3A···Br = 2.85(3) Å], see Fig. 4.15. The crystal 
lattice of 1 is further stabilized by intermolecular between the benzothiazole and 
perimidine moieties and co-planar analogous moieties in neighbouring molecules of 
1 with centroid to centroid distances of 3.859 Å and 4.133 Å, respectively, see Figs. 
4.16 and 4.17. These intermolecular interaction at distances does not reflect π-π 
stacking as they are larger than 3.5 Å. The metal complexes 2 and 3 crystallizes out in 
respective P21/n and P-1 space-groups with their unit cells occupied by four and two 
molecules, respectively.  
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The solid-state structures of the metal complexes are distorted octahedrons induced 
by their constrained bite angles:  N1-Re-N2 = 74.56(8)º for 1, N2-Re-N3 = 73.92(8)º for 
2, N1-Re-N2 = 75.7(2)º and N2-Re-N3 = 81.9(2)º for 3, see Figs. 4.18 - 4.20. The 
difference in the Re-Br bonds of 3 [Re-Br1 = 2.5033(7) Å and Re-Br2 = 2.6008(5) Å] 
illustrates the variable trans-influence of the imino (N2) and pyrrole (N1) nitrogens 
imposed onto the Br1 and Br2 atoms, respectively. The rhenium(I) halide 
coordination  bonds lengths of 1 [Re-Br = 2.6222(3) Å] and 2 [Re-Br = 2.6319(6) Å] are 
longer than the Re(V)-Br bonds of 3 which accounted to the higher acidic character 
of the complex 3’s central metal atom. No rhenium to perimidine bonds could be 
found in the Cambridge Crystallographic Database Centre (CCDC) to compare the 
ReI-Nperimidine bonds of 1 [Re-N2 = 2.257(2) Å] and 2 [Re-N2 = 2.198(2) Å] with [35]. 
The difference in the aforementioned bond distances reflects that Re(I) metal in 
atoms 1 and 2 are bonded to nitrogen atoms of different hybridizations.  Nearly 
equidistant are Re-Nbenzothiazole [2.207(2) Å] of 1 and Re-Npyridine [2.170(2) Å] bonds of 2 
when compared to the facial tricarbonylrhenium(I) complexes: fac-[Re(Habt)(CO)3Br] 
(Habt = 2-(2-aminophenyl)benzothiazole) with a Re-Nbenzothiazole bond of 2.227(2) Å 
and fac-[Re(CO)3(adp)Br] (adp = 5-amino-1,3-dimethyl-6-[(pyridin-2-
ylmethylidene)amino]pyrimidine-2,4(1H, 3H)-dione) Re-Npyridine bond of 2.166(2) Å 
[36, 37].  
  
The organometallic Re-C bonds of 1 [Re-C1 = 1.914(2) Å, Re-C2 = 1.912(3) Å and 
1.918(3) Å] and 2 [Re-C1 = 1.913(2) Å, Re-C2 = 1.904(3) Å and Re-C3 = 1.914(3) Å] 
were similar to other rhenium(I) compounds containing the facial tricarbonyl core 
[38]. For 3, the N3 atom is a dianionic nitrogen which implies that Re-N3 [1.733(5) Å] 
is a bent imido bond and the latter bond is longer than the typical range [1.698(4) – 
1.75(1) Å] of oxo-free rhenium(V) compounds containing linear phenylimido Re≡N 
bonds [39-43]. As expected, the neutral sp2 N2 atom affords a longer rhenium 
coordination bond [2.150(2) Å] of 3 in comparison to the Re=N bent imido and the 
deprotonated Re-Npyrrole [2.092(5) Å] bonds. The Re-P bond length of 3 is 2.412(1) Å 
and has a comparable bond distance to trans-[Re(apd)Br(aor)(PPh3)2] (apd = 5-
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imidopyrimidine-2,4-dione) (aor = 5-aminoorotic acid) with an Re-P bond length of 
2.456(7) Å [44].  
 
Evaluating the pyprm chelator of 2, it can be clearly established that the bond order 
of the C14-N2 [1.315(3) Å] bond is the same as its cyclic C=N bonds of pyridine [C15-
N3 = 1.357(3) Å and C16-N3 = 1.344(3) Å] and the imino bond of 3 [C5-N2 = 1.335(7) 
Å]. Furthermore, the flexibility of the N2-C11-N3 bond angle of 1 affirms that all the 
bonds connected to the C11 atom are single. Consequently, the benzothiazole and 
naphthalene moieties form a dihedral angle of 72.96º. In addition, the benzothiazole 
and naphthalene moieties lies out of the mean C1C3N2N1 basal plane by 21.51º and 
73.76º, respectively. Indicative to 1, the influence of the aliphatic imino moiety is 
emphasized by the deviation of the pyrrole and naphthalene moieties out of the 
mean Br1N3N2N1 basal plane by 11.90º and 8.85º, respectively while the 
aforementioned moieties form a dihedral angle of 20.15º. 
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Fig. 4.15: A perspective view of the dimer of 1 formed by hydrogen bonding interactions: 
N3-H3···BrA/N3A-H3A···Br = 2.85(3) Å. 
 
Fig. 4.16: An illustration showing the nearly co-planar benzothiazole moieties of adjacent 
molecules with a centroid-to-centroid distance of 3.859 Å, denoted as [I]. 
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Fig. 4.17: An illustration showing the nearly co-planar perimidine moieties of adjacent 
molecules with a centroid-to-centroid distance of 4.133 Å, denoted as [II] and [III]. 
 
 
Fig. 4.18: Thermal ellipsoid diagram (50% probability surfaces) and atom numbering scheme 
for the X-ray structure of fac-[Re(CO)3(bzpm)Br](1).  
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Fig. 4.19: Thermal ellipsoid diagram (50% probability surfaces) and atom numbering scheme 
for the X-ray structure of fac-[Re(CO)3(pypm)Br](2). 
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Fig. 4.20: Thermal ellipsoid diagram (50% probability surfaces) and atom numbering scheme 
for the X-ray structure of cis-[Re(pyrnp)Br2(PPh3)](3). 
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Table 1: Crystal data and structure refinement data. 
 1 2 3 
Chemical formula C21H13BrN3O3ReS C19H11BrN3O3Re C33H25Br2N3PRe 
Formula weight 653.51 595.42 840.55 
Temperature (K) 100(2) 100(2) 100(2) 
Crystal system Triclinic Monoclinic Triclinic 
Space group P-1 P21/n P-1 
Unit cell dimensions (Ǻ, °) a = 10.1444(7) a = 15.262(5) a = 10.2487(8) 
 b = 10.9671(8) b = 7.381(5) b = 11.2932(8) 
 c = 12.3715(8) c = 19.557(5) c = 15.0028(12) 
 α = 100.677(3) α = 90.000(5) α = 89.578(3) 
 β = 111.580(3) β = 98.023(5) β = 80.338(4) 
 γ = 98.694(3) γ = 90.000(5) γ = 71.229(3) 
V(Å3) 1220.99(15) 2181.51 1620.9(2) 
Z 2 4 2 
Density (calc.) (Mg/m3) 1.778 1.813 1.722 
Absorption coefficient (mm-1) 6.72 7.42 6.29 
F(000) 620 1120 808 
θ range for data collection (deg) 1.8; 28.0 1.6; 30.1 1.4; 29.2 
Reflections measured 19909 25474 29760 
Observed reflections [I>2σ(I)] 5844 6387 8626 
Independent reflections 5520 5651 7585 
Data/Restraints/parameters 5520/0/279 5651/0/248 7585/0/361 
Goodness of fit on F2 1.015 0.989 1.066 
Observed R, wR2 0.018; 0.042 0.023; 0.052 0.054; 0.155 
Rint 0.023 0.037 0.055 
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Table 2: Selected bond lengths [Å] and bond angles [°] for 1. 
Re-Br 2.622(2) 
Re-C1 1.914(2) 
Re-C2 1.912(3) 
Re-C3 1.918(3) 
Re-N1 2.207(2) 
Re-N2 2.257(2) 
N1-Re-N2 74.56(8) 
 
 
Table 3: Selected bond lengths [Å] and bond angles [°] for 2. 
Re-Br 2.6319(6) 
Re-C1 1.913(2) 
Re-C2 1.904(2) 
Re-C3 1.914(3) 
Re-N2 2.198(2) 
Re-N3 2.170(2) 
C14-N2 1.315(3) 
C15-N3 1.357(3) 
C16-N3 1.344(3) 
N2-Re-N3 73.92(8) 
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Chapter 5 
Conclusions and Futurework 
 
In this research study, the coordination susceptibility of N-donor heterocyclic 
multidentate chelators incorporating various biologically relevant moieties (viz. 
chromone, benzothiazole, perimidine and pyrrole) have been explored towards 
either the fac-[ReI(CO)3]+or [ReVO]3+ cores.  The isolated metal complexes were 
characterized via NMR-, IR- and UV-Vis spectroscopy and conductivity 
measurements. Single crystal X-ray analysis provided definitive confirmations of the 
structural elucidations of the respective metal complexes. The coordination 
chemistry was complemented by DFT and DNA binding studies. 
 
More specifically in chapter 3, reports the coordination chemistry of the ligands chret 
and chb to Re to afforded the di- and mononuclear rhenium(I) compounds: fac-
(Re(CO)3Br)2(μ-chret) (2) and fac-[Re(CO)3(bzch)Br] (3) respectively. However, in an 
attempt to isolate the diimine, 3,5-bis-(3-methylimino-chromone)-1H-1, 2, 4-triazole 
(prchr) in the presence of trifluoro acetic acid; a novel ligand, chrpychr was 
inadvertently isolated. Subsequently, the 1:1 molar reaction between chrpychr and 
[Re(CO)5Br] led to the formation of the rhenium(I) complex, fac-
[Re(CO)3(chrpychr)Br] (1) in low yield.  The interpretation of the IR spectra of the 
metal compounds (1-3) was supported by their simulated spectra data calculated at 
the DFT level of theory. X-ray studies concurred with the spectroscopic 
characterization, revealing the metal-induced transformation of the chb diimine into 
the bzch chelator (in 3). It also affirmed the bidentate coordination modes of the, 
chrpychr (in 1), chb (in 2) and bzch (in 3) to form new octahedral Re complexes. In 
addition, the 6-membered chelate rings of complex 1-3 had a significant influence on 
the octahedral geometries. 
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Furthermore in chapter 4, novel perimidine rhenium(I) and –(V) complexes were 
spectroscopically characterized and single crystal X-ray analysis revealed that their 
respective Re atom is in the centre of a distorted octahedrons for each complex 
imposed on by their individual constrained chelate bite angles. They form five-
membered chelates in contrast to six-membered rings for complexes discussed in 
chapter 3.CT-DNA titrations conducted with fac-[Re(CO)3(bzpm)Br](1) and fac-
[Re(CO)3(pypm)Br](2) suggested that they are partial DNA interchelators facilitated 
by pi-conjugated moeities within their respective chelators while the bulky 
triphenylphosphine co-ligand of cis-[Re(pyrnp)Br2(PPh3)](3) induced limited 
interaction between the CT-DNA and complex 3. 
 
It is envisage that this work will be expanded by utilizing different biological 
moeities appended to the 1, 3-dihydroperimidine core, see Figure 6.1. Plausible 
biologically relevant moeities could include the secondary metabolite, chromone and 
1,3,7-trimethyllumazine which is a derivative of the enzyme, Lumazine synthase [1, 
2].  The scope of the research study will also be expanded by exploring the 
anticancer properties of the formulated metal complexes against various cancer cell 
lines. In addition, Gel Electrophorises and DNA binding studies will be conducted 
on all the metal complexes to provide insight into their modes of interactions with 
DNA.  
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Figure 6.1: Generic structure of the proposed new perimidine ligands where the appended R 
groups can be the biologically relevant moieties: chromone or 1, 3, 7-trimethyllumazine. 
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